UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

~~(Mark One)~~


☒			Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended ~~June 30, 2020~~March 31, 2021


☐			Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

For the transition period from ____________ to _____________

Commission File Number: 001-38794

COVETRUS, INC.

(Exact Name of Registrant as Specified in its Charter)


Delaware						83-1448706
(State or other jurisdiction of incorporation)						(I.R.S. Employer Identification No.)

7 Custom House Street

Portland, ME 04101

Tel: (888) 280-2221

(Address, including Zip Code, and Telephone Number, including Area Code, of Registrant’s Principal Executive Offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, par value $0.01 per share

CVET

Nasdaq Global Select Market

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes

☒

☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes

☒

☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated Filer

☐☒

Accelerated Filer

☐

Non-accelerated Filer

☒☐

Smaller reporting company

☐

Emerging growth company

☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes

☐

☒

The registrant had ~~112,826,098~~136,589,404 shares of common stock outstanding as of ~~August 7, 2020.~~April 30, 2021.

TABLE OF CONTENTS


			Page
Glossary of Defined Terms and Abbreviations			3
PART I - FINANCIAL INFORMATION
Item 1. Condensed Consolidated Financial Statements (Unaudited)
Balance Sheets			35
Statements of Operations			46
Statements of Comprehensive Income (Loss)			57
Statements of Shareholders' Equity			68
Statements of Cash Flows			89
Notes to Condensed Consolidated Financial Statements
Note 1: Business Overview and Significant Accounting Policies			10

Note 2: Segment Data			11
Note 3: Revenue from Contracts with Customers			12
Note 4: Earnings (Loss) Per Share			13
Note 5: Commitments and Contingencies			13
Note 6: Income Taxes			14
Note 7: Fair Value			14
Note 8: Derivatives			16
Note 9: Accumulated Other Comprehensive Income (Loss)			17
Note 10: Redeemable Non-controlling Interests			17

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations			2618
Item 3. Quantitative and Qualitative Disclosures About Market Risk			3827
Item 4. Controls and Procedures			4028

PART II - OTHER INFORMATION
Item 1. Legal Proceedings			4229
Item 1A. Risk Factors			4229
Item 2. Unregistered Sales of Securities and Use of Proceeds			4429
Item 5. Other Information			30
Item 6. Exhibits			4530
Signatures			4631


Covetrus, Inc. 2021 Q1 Form 10-Q			2

Glossary of Defined Terms and Abbreviations


AAFCO			Association of American Feed Control Officials
Acquisition*			Our acquisition of Vets First Choice in an all-stock transaction
Adjusted EBITDA*			Adjusted EBITDA is the segment measure of profit or loss reported to the CODM. Adjusted EBITDA excludes share-based compensation, strategic consulting, transaction costs, formation of Covetrus expenses, separation programs and executive severance, carve-out operating expenses, certain IT infrastructure expenses necessary to establish ourselves as a newly public company, goodwill impairment charges, capital structure-related fees, operating lease right-of-use asset impairments, the proportionate share of the adjustments of consolidated and non-consolidated affiliates where Covetrus ownership is less than 100%, managed exits from businesses we are exiting or closing, and other income and expense items, net. Non-GAAP Adjusted EBITDA on a total segment basis is reconciled in Note 2 - Segment Data as required by ASC 280
AIP*			Annual Incentive Plan
Investment and Shareholders Agreement*			The Investment and Shareholders Agreement of Distrivet, S.A. executed on January 13, 2020
Animal Health Business*			Former Parent's spun-off animal-health business
Animal Owners*			Patients of our Customers
APAC			Asia Pacific
APVMA			Australian Pesticides and Veterinary Medicines Authority
ASC			Accounting Standards Codification
ASU			Accounting Standards Update
BEAT			Base Erosion & Anti-Abuse Tax
CEO			Chief Executive Officer
CARES			Coronavirus Aid, Relief, and Economic Security Act
CCPA			California Consumer Privacy Act
CFO			Chief Financial Officer
CODM			Chief Operating Decision Maker
COVID-19			Novel Coronavirus Disease 2019
Credit Facilities*			On February 7, 2019, we entered into a $1.5 billion syndicated credit agreement with a group of lenders for a five-year term
Customers*			Veterinarians and animal-health practitioners
CVM			Center for Veterinary Medicine
DEA			U.S. Drug Enforcement Administration
DGCL			Delaware General Corporation Law
Defendants*			The Company, our Former Parent, our former Chief Executive Officer and President, and our former Chief Financial Officer, collectively
Distribution*			All the shares of our common stock that were then owned by our Former Parent were distributed to its stockholders of record as of January 17, 2019. Concurrent with the Distribution, we paid a cash dividend of $1.2 billion to our Former Parent from loan proceeds from our newly established Term Loan Facility
Distrivet*			On April 30, 2020, we combined our subsidiary, SAHS, with Distrivet, S.A. to form a leading animal-health provider on the Iberian Peninsula. We own 50.01% of the new company, called Distrivet, a Covetrus company
EBITDA			Earnings Before Interest, Taxes, Depreciation, and Amortization
EFTA			European Free Trade Area
EFSA			European Food Safety Authority
EMA			European Medicines Agency
EPA			Environmental Protection Agency
EPS			Basic earnings (loss) per common share
ESG			Environmental, social, and corporate governance
ESPP			Employee Stock Purchase Plan
Exchange Act			Securities Exchange Act of 1934, as amended
FCMA			Fellow Chartered Management Accountant


Covetrus, Inc. 2021 Q1 Form 10-Q			3


FDA			U.S. Food and Drug Administration
FDII			Foreign-derived Intangible Income
Form 10-K			Audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2020
Form 10-Q or Report			Quarterly Report on Form 10-Q
Former Parent*			Henry Schein, Inc.
FTC			Federal Trade Commission
GAAP			Generally Accepted Accounting Principles in the United States of America
GDPR			EU General Data Protection Regulation
GFI			Guidance for Industry
GILTI			Global Intangible Low-Taxed Income
Global Technology Solutions*			The aggregation of our software services with our prescription management platform and related pharmacy services
IRS			Internal Revenue Service
ITGC			Information Technology General Controls
LIBOR			London Interbank Offered Rate
NYSE			New York Stock Exchange
NZ EPA			New Zealand Environmental Protection Authority
Revolving Credit Facility*			$300 million revolving line of credit for working capital and general corporate purposes
RSA			Restricted Stock Award
RSU			Restricted Stock Unit
SAHS*			Spain Animal Health Solutions S.L.U.
SEC			Securities and Exchange Commission
Separation*			In anticipation of the spin-off, affiliates of Covetrus purchased from certain minority holders their ownership interests in the applicable operating companies of the Animal Health Business. On February 7, 2019, our Former Parent completed the spin-off of its Animal Health Business and transferred the applicable assets, liabilities, and ownership interests to us
SG&A			Selling, general and administrative expenses
Share Sale*			On February 7, 2019 and prior to the Distribution, we sold $361 million in shares to accredited institutional investors. The proceeds from the Share Sale were paid to us and distributed to our Former Parent
SMB			Small or Medium-Sized Business
Term Loan Facility*			$1.2 billion term loan facility
Transactions			Collectively the following events, effective February 7, 2019, Vets First Choice became a wholly-owned subsidiary of Covetrus, Inc. (f/k/a HS Spinco, Inc.), a company formed by our Former Parent in connection with the spin-off of the Animal Health Business and combination with Vets First Choice
TSA			Transition Service Agreements
U.K.			United Kingdom
USDA			U.S. Department of Agriculture
Vets First Choice*			Direct Vet Marketing, Inc. (d/b/a Vets First Choice)
VMD			Veterinary Medicines Directorate
VSG*			Veterinary Study Groups, Inc.
Covetrus, Company, we, us, our, or ourselves			Covetrus, Inc. and its consolidated subsidiaries, collectively
XBRL			eXtensible Business Reporting Language

*Defined term or abbreviation is specific to CVET


Covetrus, Inc. 2021 Q1 Form 10-Q			4

Table of Contents

PART I

Item 1. Condensed Consolidated Financial Statements

COVETRUS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In millions, except share amounts)


		June 30, 2020		December 31, 2019			March 31, 2021		December 31, 2020
		(Unaudited)					(Unaudited)
ASSETS	ASSETS					ASSETS
Current assets:	Current assets:					Current assets:
Cash and cash equivalents	Cash and cash equivalents	$	414	$	130	Cash and cash equivalents	$	211	$	290
Accounts receivable, net of allowance of $6 and $8		470		426
Accounts receivable, net of allowance of $5 and $5						Accounts receivable, net of allowance of $5 and $5	518		507
Inventories, net	Inventories, net	484		636		Inventories, net	555		530
Other receivables	Other receivables	75		67		Other receivables	87		67
Prepaid expenses and other	Prepaid expenses and other	41		30		Prepaid expenses and other	51		37
Assets held for sale		—		51
Total current assets	Total current assets	1,484		1,340		Total current assets	1,422		1,431
Non-current assets:	Non-current assets:					Non-current assets:
Property and equipment, net of accumulated depreciation of $94 and $84		102		93
Operating lease right-of-use assets, net (Note 5)		127		84
Property and equipment, net of accumulated depreciation of $112 and $106						Property and equipment, net of accumulated depreciation of $112 and $106	118		116
Operating lease right-of-use assets, net						Operating lease right-of-use assets, net	111		117
Goodwill	Goodwill	1,154		1,154		Goodwill	1,187		1,187
Other intangibles, net (Note 6)		572		643
Investments and other (Note 3)		87		47
Other intangibles, net of accumulated amortization of $497 and $470						Other intangibles, net of accumulated amortization of $497 and $470	516		555
Investments and other						Investments and other	86		90
Total assets	Total assets	$	3,526	$	3,361	Total assets	$	3,440	$	3,496
LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS' EQUITY	LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS' EQUITY					LIABILITIES, MEZZANINE EQUITY, AND SHAREHOLDERS' EQUITY
Current liabilities:	Current liabilities:					Current liabilities:
Accounts payable	Accounts payable	$	429	$	520	Accounts payable	$	416	$	405
Current maturities of long-term debt and other borrowings (Note 7)		31		62
Current maturities of long-term debt and other borrowings						Current maturities of long-term debt and other borrowings	17		1
Accrued payroll and related liabilities	Accrued payroll and related liabilities	50		44		Accrued payroll and related liabilities	57		67
Accrued taxes	Accrued taxes	48		18		Accrued taxes	29		37
Other current liabilities	Other current liabilities	162		164		Other current liabilities	163		181
Liabilities held for sale		—		21
Total current liabilities	Total current liabilities	720		829		Total current liabilities	682		691
Non-current liabilities:	Non-current liabilities:					Non-current liabilities:
Long-term debt and other borrowings, net (Note 7)		1,095		1,125
Deferred taxes		41		47
Long-term debt and other borrowings, net						Long-term debt and other borrowings, net	1,054		1,068
Deferred income taxes						Deferred income taxes	23		28
Other liabilities	Other liabilities	141		94		Other liabilities	125		136
Total liabilities	Total liabilities	1,997		2,095		Total liabilities	1,884		1,923
Commitments and contingencies (Note 10)
Commitments and contingencies (Note 5)						Commitments and contingencies (Note 5)	0		0
Mezzanine equity:	Mezzanine equity:					Mezzanine equity:
Redeemable non-controlling interests (Note 11)		9		10
Redeemable series A convertible preferred stock, $0.01 par value, $1,000 per share liquidation preference, 250,000 shares authorized, issued, and outstanding as of June 30, 2020 (Note 12)		244		—
Redeemable non-controlling interests (Note 10)						Redeemable non-controlling interests (Note 10)	36		36
Shareholders' equity:	Shareholders' equity:					Shareholders' equity:
Common stock, $0.01 par value per share, 675,000,000 shares authorized; 112,674,657 shares issued and outstanding as of June 30, 2020; 111,620,507 shares issued and outstanding as of December 31, 2019		1		1
Accumulated other comprehensive loss (Note 13)		(107)		(86)
Common stock, $0.01 par value per share, 675,000,000 shares authorized; 136,342,036 shares issued and outstanding as of March 31, 2021; 136,017,964 shares issued and outstanding as of December 31, 2020						Common stock, $0.01 par value per share, 675,000,000 shares authorized; 136,342,036 shares issued and outstanding as of March 31, 2021; 136,017,964 shares issued and outstanding as of December 31, 2020	1		1
Accumulated other comprehensive loss (Note 9)						Accumulated other comprehensive loss (Note 9)	(75)		(66)
Additional paid-in capital	Additional paid-in capital	2,404		2,381		Additional paid-in capital	2,637		2,629
Accumulated deficit	Accumulated deficit	(1,022)		(1,040)		Accumulated deficit	(1,043)		(1,027)
Total shareholders’ equity	Total shareholders’ equity	1,276		1,256		Total shareholders’ equity	1,520		1,537
Total liabilities, mezzanine equity, and shareholders’ equity	Total liabilities, mezzanine equity, and shareholders’ equity	$	3,526	$	3,361	Total liabilities, mezzanine equity, and shareholders’ equity	$	3,440	$	3,496

See notes to unaudited condensed consolidated financial statements.


Covetrus, Inc. 2021 Q1 Form 10-Q			5

Table of Contents

COVETRUS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(In millions, except per share amounts) (Unaudited)

Three Months Ended June 30, Six Months Ended June 30,
2020 2019 2020 2019
Net sales (Note 4) $ 1,026 $ 1,009 $ 2,091 $ 1,950
Cost of sales 834 816 1,696 1,580
Gross profit 192 193 395 370
Operating expenses:
Selling, general and administrative 196 198 419 384
Operating loss (4) (5) (24) (14)
Other income (expense):
Interest income 1 2 1 3
Interest expense (14) (15) (28) (26)
Other, net (Note 3) 76 13 75 15
Income (loss) before taxes and equity in earnings of affiliates 59 (5) 24 (22)
Income tax expense (Note 14) (6) (5) (4) (1)
Equity in net earnings of affiliates (Note 3) 1 — 1 —
Net income (loss) 54 (10) 21 (23)
Less: net income attributable to redeemable non-controlling interests — — (1) —
Net income (loss) attributable to Covetrus $ 54 $ (10) $ 20 $ (23)
Earnings (loss) per share attributable to Covetrus: (Note 15)
Basic $ 0.40 $ (0.09) $ 0.15 $ (0.22)
Diluted $ 0.40 $ (0.09) $ 0.15 $ (0.22)
Weighted-average common shares outstanding:
Basic 112 112 112 103
Diluted 113 112 113 103


	Three Months Ended March 31,
		2021		2020
Net sales (Note 3)		$	1,102	$	1,065
Cost of sales		892		863
Gross profit		210		202
Operating expenses:
Selling, general and administrative		213		222


Operating income (loss)		(3)		(20)
Other income (expense):
Interest income		0		0
Interest expense		(9)		(14)
Other, net		0		(1)
Income (loss) before taxes and equity in earnings of affiliates		(12)		(35)
Income tax benefit (expense) (Note 6)		(4)		2

Net income (loss)		(16)		(33)
Net (income) loss attributable to redeemable non-controlling interests		0		0
Net income (loss) attributable to Covetrus		$	(16)	$	(33)

Earnings (loss) per share attributable to Covetrus: (Note 4)
Basic		$	(0.11)	$	(0.30)
Diluted		$	(0.11)	$	(0.30)
Weighted-average common shares outstanding:
Basic		136		112
Diluted		136		112

See notes to unaudited condensed consolidated financial statements.


Covetrus, Inc. 2021 Q1 Form 10-Q			6

Table of Contents

COVETRUS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In millions) (Unaudited)


		Three Months Ended June 30,						Six Months Ended June 30,					Three Months Ended March 31,
		2020		2019		2020		2019			2021		2020
Net income (loss)	Net income (loss)	$	54	$	(10)	$	21	$	(23)	Net income (loss)	$	(16)	$	(33)
Other comprehensive income (loss), net of tax:	Other comprehensive income (loss), net of tax:									Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	Foreign currency translation gain (loss)	6		4		(16)		5		Foreign currency translation gain (loss)	(11)		(22)

Unrealized gain (loss) on derivative instruments		1		—		(7)		—
Gain (loss) on derivative instruments										Gain (loss) on derivative instruments	2		(8)

Total other comprehensive income (loss)	Total other comprehensive income (loss)	7		4		(23)		5		Total other comprehensive income (loss)	(9)		(30)
Comprehensive income (loss)	Comprehensive income (loss)	61		(6)		(2)		(18)		Comprehensive income (loss)	(25)		(63)

Comprehensive (income) loss attributable to redeemable non-controlling interests:	Comprehensive (income) loss attributable to redeemable non-controlling interests:									Comprehensive (income) loss attributable to redeemable non-controlling interests:
Net income		—		—		(1)		—
Net (income) loss										Net (income) loss	0		0
Foreign currency translation (gain) loss	Foreign currency translation (gain) loss	—		—		(2)		1		Foreign currency translation (gain) loss	(1)		(1)
Comprehensive income attributable to redeemable non-controlling interests		—		—		(3)		1
Comprehensive (income) loss attributable to redeemable non-controlling interests										Comprehensive (income) loss attributable to redeemable non-controlling interests	(1)		(1)
Comprehensive income (loss) attributable to Covetrus	Comprehensive income (loss) attributable to Covetrus	$	61	$	(6)	$	(5)	$	(17)	Comprehensive income (loss) attributable to Covetrus	$	(26)	$	(64)

See notes to unaudited condensed consolidated financial statements.


Covetrus, Inc. 2021 Q1 Form 10-Q			7

Table of Contents

COVETRUS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

(In millions, except share amounts) (Unaudited)

Three Months Ended June 30, 2020
Common Stock Additional
Paid-in
Capital Accumulated Deficit Accumulated Other Comprehensive Loss Total Shareholders' Equity
Shares Amount
Balance at March 31, 2020 111,854,439 $ 1 $ 2,390 $ (1,074) $ (116) $ 1,201
Net income attributable to Covetrus — — — 54 — 54
Issuance of shares in connection with share-based compensation plans 820,218 — 4 — — 4
Share-based compensation — — 10 — — 10
Series A preferred stock cash dividend — — — (2) — (2)
Other comprehensive income — — — — 9 9
Balance at June 30, 2020 112,674,657 $ 1 $ 2,404 $ (1,022) $ (107) $ 1,276
Six Months Ended June 30, 2020
Common Stock Additional
Paid-in
Capital Accumulated Deficit Accumulated Other Comprehensive Loss Total Shareholders' Equity
Shares Amount
Balance at December 31, 2019 111,620,507 $ 1 $ 2,381 $ (1,040) $ (86) $ 1,256
Net income attributable to Covetrus — — — 20 — 20
Issuance of shares in connection with share-based compensation plans 1,054,150 — 4 — — 4
Share-based compensation — — 19 — — 19
Series A preferred stock cash dividend — — — (2) — (2)
Other comprehensive loss — — — — (21) (21)
Balance at June 30, 2020 112,674,657 �� $ 1 $ 2,404 $ (1,022) $ (107) $ 1,276




















	Three Months Ended March 31, 2021
	Common Stock			Accumulated Other Comprehensive Income (Loss)		Additional Paid-in Capital		Accumulated Deficit		Total Shareholders' Equity
	Shares	Amount
Balance at December 31, 2020	136,017,964	$	1	$	(66)	$	2,629	$	(1,027)	$	1,537
Net income (loss) attributable to Covetrus	—	—		—		—		(16)		(16)





Issuance of shares in connection with share-based compensation plans, net of shares withheld for taxes	324,072	—		—		(3)		—		(3)
Share-based compensation	—	—		—		11		—		11



Other comprehensive income (loss)	—	—		(9)		—		—		(9)
Balance at March 31, 2021	136,342,036	$	1	$	(75)	$	2,637	$	(1,043)	$	1,520



















	Three Months Ended March 31, 2020
	Common Stock			Accumulated Other Comprehensive Income (Loss)		Additional Paid-in Capital		Accumulated Deficit		Total Shareholders' Equity
	Shares	Amount
Balance at December 31, 2019	111,620,507	$	1	$	(86)	$	2,339	$	(1,001)	$	1,253
Net income (loss) attributable to Covetrus	—	—		—		—		(33)		(33)





Issuance of shares in connection with share-based compensation plans, net of shares withheld for taxes	233,932	—		—		0		—		0
Share-based compensation	—	—		—		9		—		9


Other comprehensive income (loss)	—	—		(30)		—		—		(30)
Balance at March 31, 2020	111,854,439	$	1	$	(116)	$	2,348	$	(1,034)	$	1,199

See notes to unaudited condensed consolidated financial statements.

~~Table of Contents~~

~~COVETRUS, INC.~~

~~CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY~~

~~(In millions, except share amounts) (Unaudited) (Continued)~~

Three Months Ended June 30, 2019
Common Stock Additional
Paid-in
Capital Accumulated Deficit Accumulated Other Comprehensive Loss Net Former Parent Investment Total Shareholders' Equity
Shares Amount
Balance at March 31, 2019 111,576,343 $ 1 $ 2,395 $ (21) $ (81) $ — $ 2,294
Net (loss) income attributable to Covetrus — — — (12) — 2 (10)
Dividend to Former Parent — — (21) — — — (21)
Shares held in escrow expected to be canceled — — (30) — — — (30)
Net decrease in Former Parent investment — — — — — (2) (2)
Issuance of shares in connection with share-based compensation plans 356,148 — 2 — — — 2
Share-based compensation — — 10 — — — 10
Other comprehensive income — — — — 4 — 4
Balance at June 30, 2019 111,932,491 $ 1 $ 2,356 $ (33) $ (77) $ — $ 2,247
Six Months Ended June 30, 2019
Common Stock Additional
Paid-in
Capital Accumulated Deficit Accumulated Other Comprehensive Loss Net Former Parent Investment Total Shareholders' Equity
Shares Amount
Balance at December 29, 2018 — $ — $ — $ — $ (82) $ 1,576 $ 1,494
Net (loss) income attributable to Covetrus^(a)
— — — (33) — 10 (23)
Dividend to Former Parent — — (21) — — (1,153) (1,174)
Issuance of shares at Separation (including Share Sale investors) 71,693,426 1 608 — — (609) —
Issuance of shares in connection with the Acquisition 39,742,089 — 1,772 — — — 1,772
Shares held in escrow expected to be canceled — — (30) — — — (30)
Net increase in Former Parent investment — — — — — 176 176
Issuance of shares in connection with share-based compensation plans 496,976 — 2 — — — 2
Share-based compensation — — 25 — — — 25
Other comprehensive income — — — — 5 — 5
Balance at June 30, 2019 111,932,491 $ 1 $ 2,356 $ (33) $ (77) $ — $ 2,247

~~(a) Net income earned from January 1, 2019 through February 7, 2019 is attributed to the Former Parent as it was the sole shareholder prior to February 7, 2019.~~Covetrus, Inc. 2021 Q1 Form 10-Q

~~See notes to condensed consolidated financial statements.~~

Table of Contents

COVETRUS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In millions) (Unaudited)

Six Months Ended June 30,
2020 2019
Cash flows from operating activities:
Net income (loss) $ 21 $ (23)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization 82 71
Amortization of right-of-use assets 12 10
Gain on divestiture of a business (73) —
Share-based compensation expense 19 25
Benefit for deferred income taxes (2) (9)
Gain on affiliate investment — (11)
Amortization of debt issuance costs 3 3
Other (2) —
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable, net (56) (13)
Inventories, net 130 21
Other assets and liabilities (14) (77)
Accounts payable and accrued expenses (66) 6
Net cash provided by operating activities 54 3
Cash flows from investing activities:
Purchases of property and equipment (24) (21)
Payments related to equity investments and business acquisitions, net of cash acquired (13) (25)
Proceeds from divestiture of a business, net 104 —
Proceeds from sale of property and equipment 4 1
Net cash provided by (used for) investing activities 71 (45)
Cash flows from financing activities:
Proceeds from revolving credit facility 190 —
Repayment of revolving credit facility (190) —
Proceeds from issuance of debt — 1,220
Principal payments of debt (62) (43)
Debt issuance and amendment costs (5) (24)
Dividend paid to Former Parent — (1,174)
Issuance of common shares in connection with share-based compensation plans 4 3
Net transfers from Former Parent — 165
Proceeds from issuance of Series A preferred stock 250 —
Series A preferred stock issuance costs (6) —
Series A preferred stock dividend (2) —
Acquisition payment (17) —
Acquisitions of non-controlling interests in subsidiaries — (74)
Net cash provided by financing activities 162 73
Effect of exchange rate changes on cash and cash equivalents (3) 1
Net change in cash and cash equivalents 284 32
Cash and cash equivalents, beginning of period 130 23
Cash and cash equivalents, end of period $ 414 $ 55

~~Table of Contents~~

COVETRUS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions) (Unaudited) (Continued)
Six Months Ended June 30,
2020 2019
Supplemental disclosure of cash paid for:
Interest $ 23 $ 22
Income taxes $ 10 $ 10
Amounts included in the measurement of operating lease liabilities $ 13 $ 12
Supplemental disclosures of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new operating lease liabilities $ 57 $ 71
Deconsolidation of a subsidiary (Note 3) $ 15 $ —


	Three Months Ended March 31,
	2021		2020
Cash flows from operating activities:
Net income (loss)	$	(16)	$	(33)
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:
Depreciation and amortization	43		40
Amortization of right-of-use assets	3		6


Gain on sale of property and equipment	0		(1)

Share-based compensation expense	11		9

Benefit for deferred income taxes	(3)		(5)



Amortization of debt issuance costs	1		1

Other	3		1
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable, net	(18)		(112)
Inventories, net	(33)		44
Other assets and liabilities	(51)		5
Accounts payable and accrued expenses	1		(31)
Net cash provided by (used for) operating activities	(59)		(76)
Cash flows from investing activities:
Purchases of property and equipment	(13)		(11)


Proceeds from sale of property and equipment	0		4
Net cash provided by (used for) investing activities	(13)		(7)
Cash flows from financing activities:
Proceeds from revolving credit facility	0		190


Principal payments of debt	0		(17)
Debt issuance and amendment costs	0		(5)


Issuance of common shares in connection with share-based compensation plans, net of shares withheld for taxes	(2)		0






Acquisition payment	0		(9)
Acquisitions of non-controlling interests in subsidiaries	(1)		0
Net cash provided by (used for) financing activities	(3)		159
Effect of exchange rate changes on cash and cash equivalents	(4)		(1)
Net change in cash and cash equivalents	(79)		75
Cash and cash equivalents, beginning of period	290		130
Cash and cash equivalents, end of period	$	211	$	205

Supplemental disclosures of non-cash investing and financing activities:

Right-of-use assets obtained in exchange for new operating lease liabilities	$	3	$	46

See notes to unaudited condensed consolidated financial statements.


Covetrus, Inc. 2021 Q1 Form 10-Q			9

Table of Contents

COVETRUS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In millions) (Unaudited)

1. ~~Business Overview and Significant Accounting Policies~~BUSINESS OVERVIEW AND SIGNIFICANT ACCOUNTING POLICIES

Business

~~Covetrus, Inc. (“Covetrus,” “Company,” “we,” “our,” “us,” or “ourselves”) is~~We are a global animal-health technology and services company dedicated to supporting the companion, equine, and large-animal veterinary markets. On February 7, 2019, Covetrus became an independent company through the consummation of the spin-off by Henry Schein (“Former Parent”) of its animal-health business (“Animal Health Business”) and the completion of its acquisition of Direct Vet Marketing, Inc. (d/b/a Vets First Choice) (“Vets First Choice”). On February 8, 2019, Covetrus began trading on the Nasdaq Stock Market. Accordingly, results provided in accordance with generally accepted accounting principles in the United States of America (“GAAP”) reflect the operations of the Animal Health Business from January 1, 2019 to June 30, 2019 and Vets First Choice for the period from February 8, 2019 to June 30, 2019.

Basis of Presentation and Principles of Consolidation

The accompanying balance sheet as of December 31, ~~2019,~~2020, which was derived from audited financial statements, and the unaudited condensed consolidated financial statements as of and for the ~~six~~three months ended ~~June 30, 2020,~~March 31, 2021, have been prepared in accordance with applicable rules and regulations of the ~~Securities and Exchange Commission (the “SEC”)~~SEC for interim financial reporting. Pursuant to those rules and regulations, we omitted certain information and disclosures normally included in annual financial statements prepared in accordance with GAAP.

In our opinion, the accompanying condensed consolidated financial statements reflect all recurring adjustments and transactions necessary for a fair statement of our financial position, results of operations, and cash flows for the interim periods presented. Such operating results are not necessarily indicative of annual or future results. These condensed consolidated financial statements and notes should be read in conjunction with the ~~audited consolidated financial statements and notes included in our Annual Report on~~ Form 10-K ~~for the year ended December 31, 2019 (“Form 10-K”)~~ filed with the SEC on March ~~3, 2020.~~1, 2021.

The accompanying unaudited condensed consolidated financial statements include the operations of the Company, as well as those of our wholly-owned and majority-owned subsidiaries from their respective dates of inception or acquisition. All significant intercompany transactions and balances were eliminated in consolidation. Investments in unconsolidated affiliates, which are 20% to 50.01% owned, or investments of less than 20% in which we could influence the operating or financial decisions, are accounted for under the equity method.

~~Certain prior period amounts were reclassified or rounded to conform to the presentation of the current period.~~

~~Redeemable Convertible Preferred Stock~~

We classify our redeemable convertible preferred stock as mezzanine equity on our condensed consolidated balance sheets because it is redeemable at the option of holders upon a change of control as defined in the Certificate of Designation, Preferences and Rights for the Series A Preferred Stock (the “Certificate of Designations”), which is considered an event outside of our control. We recorded redeemable convertible preferred stock at fair value upon issuance, net of issuance costs. Our redeemable convertible preferred stock is not currently redeemable, nor is it probable of redemption. If and when a change of control becomes probable, we will accrete the redeemable convertible preferred stock to redemption value.

Accounting Pronouncements

~~Adopted~~

•As of January 1, ~~2019,~~2021, we adopted Accounting Standards Codification Topic 326, Credit Losses (“Topic 326”) which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost, including accounts receivable. Topic 326 is effective for interim and annual reporting periods beginning after December 15, 2019 and is required to be adopted using the modified retrospective basis, with a cumulative-effect adjustment to Retained earnings (Accumulated deficit) as of the beginning of the first reporting period in which the guidance of Topic 326 is effective. The adoption of Topic 326 did not have a material impact on the results of our condensed consolidated financial statements.

~~Table of Contents~~

~~COVETRUS, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(In millions) (Unaudited)~~

~~To be Adopted~~

•ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes,” which removes specific technical exceptions to general principles found in Topic 740, items that often produce information that investors have ~~a hard time~~difficulty understanding and simplifies the accounting for income taxes. The ~~standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early~~ adoption ~~permitted. We are evaluating the anticipated impact~~ of this ~~standard~~ASU did not have a material impact on the results of our condensed consolidated financial ~~statements as well as timing of adoption.~~statements.

•ASU 2020-04, “Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,” provides optional guidance for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting for contracts, hedging relationships, and other transactions that reference ~~the London Interbank Offered Rate (“LIBOR”).~~LIBOR. The standard is currently effective and upon adoption may be applied prospectively to contract modifications made on or before December 31, 2022. ~~We are evaluating~~Our debt agreements and interest rate swaps that utilize LIBOR have not yet discontinued the use of LIBOR and, therefore, this ASU is not yet effective for us. Because our interest rate swaps mature on July 31, 2021, we do not expect an accounting burden, or the relief provided by this ASU for hedging relationships, to impact of the ~~LIBOR transition and this optional relief guidance on~~results of our condensed consolidated financial statements.

~~2. Novel Coronavirus Disease 2019 (“COVID-19”)~~

The ~~COVID-19 pandemic has resulted in social distancing~~banking syndicate associated with our Credit Facilities intends to cease using the 1-week and 2-month USD LIBOR at the end of 2021, with the other ~~measures that were instituted in various localities around the world. These measures led~~USD Tenors to phased temporary closures of non-essential businesses throughout many of the regions in which we conduct operations. However, veterinary care has been deemed an essential business in most of these regions and wecease June 30, 2023. We will continue to ~~deliver products~~monitor, and, services to our customers and their animal-owner clients. In addition, most of our customers are generally able to continue their operations through new social distancing guidelines which, depending on local regulations, can include telehealth and animal curbside check-in and drop-off at clinics. As a result, through June 30, 2020, we experienced limited disruption to our results of operations from the COVID-19 pandemic. However, the COVID-19 pandemic has created volatility and unpredictability to our business, including shifts in timing and channel mix, reduced travel and entertainment expenses due to travel restrictions, as well as other changes.

~~We believe our allowance for credit losses related to our accounts receivable is adequate as of June 30, 2020, due~~ to the ~~essential nature~~extent our Credit Facilities require amendment to reflect a replacement rate prior to December 31, 2022, we will evaluate the benefits of our customers' businesses, as noted above, as well as the historic behavior of our large customer base. As the COVID-19 pandemic continues, there could be an increase in the aging of our accounts receivable, however, we do not anticipate a significant increase in defaults for such accounts receivable.

During the first quarter ended March 31, 2020, we experienced a sustained decline in our share price and a resulting decrease in our market capitalization due to the overall macroeconomic effects of the COVID-19 pandemic. Due toadopting this overall market decline and the uncertainty surrounding COVID-19, we concluded that a triggering event occurred and conducted an interim impairment review of our goodwill as of March 31, 2020. We tested for goodwill impairment by quantitatively comparing the fair value of our North America reporting unit (the only reporting unit currently bearing goodwill) to its carrying amount. Using the income-based approach, fair value exceeded the carrying amount as of March 31, 2020. We did not experience triggering events during the second quarter ended June 30, 2020.

~~We took the following actions to help ensure that our business has flexibility to mitigate potential effects from continued global economic pressure:~~

•During the quarter ended March 31, 2020, we borrowed funds under our revolving line of credit to increase our cash position and provide flexibility. In May 2020, we used a portion of the $244 million in aggregate net proceeds from the issuance of our Series A Convertible Preferred Stock to repay borrowings under our revolving line of credit. See ~~Note 7 - Long-term Debt and Other Borrowings, Net~~ ~~and~~ ~~Note 12 - Redeemable Series A Convertible Preferred Stock.~~

•~~We reduced our non-critical, near-term planned capital expenditures.~~

•~~We negotiated for extended payment terms on certain contracts.~~

•~~We managed our inventory levels in line with expected demand.~~

•We instituted cost containment measures including temporary executive, board, and other senior-level employee compensation reductions, employee furloughs in certain European countries, certain shift eliminations, a temporary hiring freeze, discretionary spending deferrals, deferred payroll taxes as available under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”), and suspended our 401(k)-employer match.ASU.


Covetrus, Inc. 2021 Q1 Form 10-Q			10

Table of Contents

COVETRUS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In millions) (Unaudited)

Some of these actions have been eased alongside our improved business performance and the recovery in our end-market. For example, in July, we returned to pre-COVID-19 compensation levels and, in August, we expect to reinstate our 401(k)-employer match. Hiring for our business was strictly limited, especially in response to the COVID-19 pandemic; however, we are relaxing the restrictions we instituted as part of our temporary hiring freeze. We continue to monitor our business performance and intend to take a cautious, but balanced approach in managing our expenses in light of uncertainty created by the COVID-19 pandemic.

~~Risk and Uncertainties~~2. SEGMENT DATA

The ~~duration~~following tables reflect our segment and ~~severity of COVID-19-related potential disruptions~~Corporate information and ~~the actions we have taken, and may take in the future, in response thereto, involve risks and uncertainties, and it is not possible at this time~~reconciles Adjusted EBITDA for reportable segments to estimate the impact that COVID-19 could have on our business. The impact of COVID-19 on various business activities in affected countries could adversely affect our estimates, results of operations, and financial condition.consolidated Net income (loss) attributable to Covetrus:

~~3. Divestiture and Equity Method Investment~~

~~Divestiture~~

On April 1, 2020, we completed the divestiture of our scil animal-care business (“scil”) to Heska Corporation for $110 million pursuant to an amended purchase agreement. The cash flow impact of the transaction is $104 million which represents gross proceeds, net of cash included in the sale.

~~The sale of scil resulted in a pre-tax gain of $73 million that was recognized during the three months ended June 30, 2020 and included in~~ ~~Other, net~~ ~~in our condensed consolidated statements of operation.~~

~~Equity Method Investment~~

On April 30, 2020, we completed the previously announced combination of our subsidiary, Spain Animal Health Solutions S.L.U. (“SAHS”), with Distrivet, S.A. to form a leading animal-health provider on the Iberian Peninsula. We contributed SAHS by means of a contribution in kind of all the shares of SAHS in exchange for the transfer of shares from shareholders of Distrivet, S.A. (“Distrivet Shareholders”). In addition, at closing, we made a payment of $11 million, and we are obligated to make an additional payment of $11 million on the one-year anniversary of the closing of the combination. As a result of these transactions, we now own 50.01% of the new company, called Distrivet, a Covetrus company (“Distrivet”).

Based on Distrivet's governance structure, we do not have power over key financial and operating decisions that are made in the ordinary course of business. Accordingly, our investment in Distrivet is accounted for under the equity method and Distrivet is considered a related party. See ~~Note 17 - Related Party Transactions.~~

The Investment and Shareholders Agreement of Distrivet, S.A. (“Agreement”) executed on January 13, 2020, contains put and call options on the shares owned by the Distrivet Shareholders, representing up to 49.99%, that are exercisable at fair market value based on floor and ceiling prices tied to Earnings Before Interest, Taxes, Depreciation, and Amortization (“EBITDA”) multiples as specified in the Agreement. See ~~Note 9 - Fair Value.~~

During the three months ended June 30, 2020, we deconsolidated SAHS, remeasured our retained investment initially at a fair value of $45 million, which was included in Investments and other in our condensed consolidated balance sheet, and recognized a gain of $1 million, which was included in Other, net in our condensed consolidated statements of operation. The fair value was measured using third-party valuation models and was determined using both the market approach and income approach, which includes discounted expected cash flows. As of June 30, 2020, the carrying amount of our investment in Distrivet was $47 million.


	At and For the Three Months Ended March 31, 2021
	North America		Europe		APAC & Emerging Markets		Corporate		Eliminations		Total
Net sales	$	635	$	361	$	112	$	0	$	(6)	$	1,102
Adjusted EBITDA	$	52	$	21	$	10	$	(26)	$	0	$	57
Total assets	$	2,948	$	672	$	189	$	1,216	$	(1,585)	$	3,440

Reconciliation of Net income (loss) attributable to Covetrus to Adjusted EBITDA:
Net income (loss) attributable to Covetrus											$	(16)
Plus: Depreciation and amortization											43
Plus: Interest expense, net											9
Plus: Income tax (benefit) expense											4
Earnings (loss) before interest, taxes, depreciation, and amortization											40
Plus: Share-based compensation											11
Plus: Strategic consulting											2
Plus: Transaction costs (a)											1


Plus: Formation of Covetrus (b)											2

Plus: Equity method investment and non-consolidated affiliates (c)											1



Adjusted EBITDA											$	57


(a) Includes legal, accounting, tax, and other professional fees incurred in connection with acquisitions and divestitures
(b) Includes professional and consulting fees, and other costs incurred in connection with the separation from Former Parent and establishing Covetrus as an independent public company
(c) Includes the proportionate share of the adjustments to EBITDA of consolidated and non-consolidated affiliates where Covetrus ownership is less than 100%


Covetrus, Inc. 2021 Q1 Form 10-Q			11

Table of Contents

COVETRUS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In millions) (Unaudited)


	At and For the Three Months Ended March 31, 2020
	North America		Europe		APAC & Emerging Markets		Corporate		Eliminations		Total
Net sales	$	550	$	422	$	95	$	0	$	(2)	$	1,065
Adjusted EBITDA	$	41	$	18	$	7	$	(18)	$	0	$	48
Total assets	$	3,063	$	725	$	128	$	787	$	(1,216)	$	3,487

Reconciliation of Net income (loss) attributable to Covetrus to Adjusted EBITDA:
Net income (loss) attributable to Covetrus											$	(33)
Plus: Depreciation and amortization											40
Plus: Interest expense, net											14
Plus: Income tax (benefit) expense											(2)
Earnings (loss) before interest, taxes, depreciation, and amortization											19
Plus: Share-based compensation											9
Plus: Strategic consulting											4
Plus: Transaction costs (a)											7
Plus: Separation programs and executive severance											1

Plus: IT infrastructure (b)											1
Plus: Formation of Covetrus (c)											6
Plus: Capital Structure											1



Adjusted EBITDA											$	48

(a) Includes legal, accounting, tax, and other professional fees incurred in connection with acquisitions and divestitures
(b) Includes certain IT infrastructure expenses necessary to establish ourselves as a newly public company
(c) Includes professional and consulting fees, duplicative costs associated with transition service agreements, and other costs incurred in connection with the separation from Former Parent and establishing Covetrus as an independent public company

See Note 3 - Revenue from Contracts with Customers for our revenue disaggregated by major product category and reportable segment.

3. REVENUE FROM CONTRACTS WITH CUSTOMERS

Disaggregation of Revenue

The tables below present our revenue disaggregated by major product category and reportable segment.

Three Months Ended June 30, 2020
Supply Chain Services Software
Solutions Prescription Management Eliminations Total
North America $ 495 $ 19 $ 110 $ (22) $ 602
Europe 342 2 — (2) 342
APAC & Emerging Markets 83 2 — — 85
Eliminations (3) — — — (3)
Total Net sales $ 917 $ 23 $ 110 $ (24) $ 1,026
Three Months Ended June 30, 2019
Supply Chain Services Software
Solutions Prescription Management Eliminations Total
North America $ 472 $ 20 $ 67 $ (7) $ 552
Europe 370 3 — (3) 370
APAC & Emerging Markets 88 2 — — 90
Eliminations (3) — — — (3)
Total Net sales $ 927 $ 25 $ 67 $ (10) $ 1,009
Six Months Ended June 30, 2020
Supply Chain Services Software Solutions Prescription Management Eliminations Total
North America $ 956 $ 40 $ 195 $ (39) $ 1,152
Europe 766 4 — (6) 764
APAC & Emerging Markets 176 4 — — 180
Eliminations (5) — — — (5)
Total Net sales $ 1,893 $ 48 $ 195 $ (45) $ 2,091
Six Months Ended June 30, 2019
Supply Chain Services Software Solutions Prescription Management Eliminations Total
North America $ 915 $ 42 $ 100 $ (8) $ 1,049
Europe 733 5 — (7) 731
APAC & Emerging Markets 172 4 — — 176
Eliminations (6) — — — (6)
Total Net sales $ 1,814 $ 51 $ 100 $ (15) $ 1,950

~~Contract Balances~~

Contract balances represent amounts presented in the condensed consolidated balance sheets when we have either transferred goods or services to the customer or the customer has paid consideration to us under the contract. These contract balances include accounts receivable, contract assets, and contract liabilities.



















	Three Months Ended March 31, 2021
	Supply Chain Services		Software Services		Prescription Management		Eliminations		Total
North America	$	525	$	20	$	112	$	(22)	$	635
Europe	364		3		0		(6)		361
APAC & Emerging Markets	109		3		0		0		112
Eliminations	(6)		0		0		—		(6)
Total Net sales	$	992	$	26	$	112	$	(28)	$	1,102

	Three Months Ended March 31, 2020
	Supply Chain Services		Software Services		Prescription Management		Eliminations		Total
North America	$	462	$	20	$	84	$	(16)	$	550
Europe	424		2		0		(4)		422
APAC & Emerging Markets	93		2		0		0		95
Eliminations	(2)		0		0		—		(2)
Total Net sales	$	977	$	24	$	84	$	(20)	$	1,065

~~Table of Contents~~

~~COVETRUS, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(In millions) (Unaudited)~~

~~Accounts Receivable~~

Accounts receivable are recognized at the amount invoiced and the carrying amount is reduced by an allowance for credit losses. Our estimation of current expected credit losses, with respect to receivables and recognition of allowances that, when deducted from the balance of the receivables, represent the net amounts expected to be collected. We do not consider there to be significant concentrations of credit risk with regard to trade receivables due to the short-term nature of our accounts, our large customer base, and strong historical experience collecting receivables. The allowance for credit losses is based on a number of factors which include reviewing delinquent accounts receivable, historical data, experience, customer types, creditworthiness, and economic trends. From time to time, we adjust our assumptions for anticipated changes in any of these or other factors expected to affect collectability, and the allowance for credit losses is reviewed quarterly for any required adjustments. Accounts receivable are written-off when it is probable that all contractual payments due will not be collected.

~~Contract Assets~~

Contract assets include amounts related to any conditional right to consideration for work completed as of the reporting date and generally represent amounts owed to us by customers, but not yet billed. Contract assets are transferred to Accounts receivable when the right becomes unconditional. Current contract assets are included in Prepaid expenses and other and non-current contract assets are included in Investments and other within the condensed consolidated balance sheets. The contract assets primarily relate to the bundled arrangements for the sale of equipment and consumables and sales of term software licenses. Current and non-current contract asset balances as of June 30, 2020 and December 31, 2019 were not material.

~~Contract Liabilities~~

Contract liabilities are comprised of advance payments and deferred revenue amounts. Contract liabilities are transferred to revenue once the performance obligation has been satisfied. Current contract liabilities are included in Other current liabilities and non-current contract liabilities are included in Other liabilities within the condensed consolidated balance sheets. The contract liabilities primarily relate to advance payments from customers and upfront payments for service arrangements provided over time. The current portion of contract liabilities of $29 million at June 30, 2020 and $37 million at December 31, 2019 were reported in Other current liabilities. Amounts related to non-current contract liabilities were not material.

~~Performance Obligations~~

~~Estimated future revenues expected to be generated from long-term contracts with unsatisfied performance obligations as of June 30, 2020 were not material.~~

~~5. Leases~~

The lease for our compounding facility and office space in Arizona commenced on January 1, 2020, which increased our operating lease right-of-use assets and liabilities by $19 million. This facility has a lease term of 14 years. We also commenced or extended various other facility and equipment operating leases which individually were not material.

~~6. Other Intangibles, Net~~

~~Other intangibles, net includes customer relationships, trademarks, patents, product development, and non-compete arrangements.~~

~~The following table presents the balances within the condensed consolidated balance sheets as of:~~

June 30, 2020 December 31, 2019
Gross definite-lived intangible assets $ 993 $ 1,001
Less: Accumulated amortization (421) (358)
Other intangibles, net $ 572 $ 643

~~Table of Contents~~

~~COVETRUS, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(In millions) (Unaudited)~~

~~The following table presents our amortization expense:~~

Three Months Ended June 30,
Location 2020 2019
Cost of sales $ 1 $ 1
Selling, general and administrative 32 33
Total amortization expense $ 33 $ 34

~~7. Long-term Debt and Other Borrowings, Net~~

~~As of June 30, 2020, our Long-term debt and other borrowings, net consisted of the following:~~

Commencement Date Maturity Date June 30,
2020 December 31, 2019
Revolving line of credit February 2019 February 2024 $ — $ —
Term loan payable; quarterly installments of $15 million began March 31, 2020 with balloon payment due at maturity February 2019 February 2024 1,140 1,200
Loan payable with balloon payment due at maturity February 2019 March 2023 5 6
Finance lease obligations 1 1
Total debt and other borrowings 1,146 1,207
Less: current maturities (31) (62)
Total Long-term debt and other borrowings 1,115 1,145
Less: unamortized debt discount (20) (20)
Total Long-term debt and other borrowings, net $ 1,095 $ 1,125

~~The amount available for borrowing under the revolving line of credit as of June 30, 2020 was $299 million, subject to covenant restrictions.~~

~~In February 2020, our credit facility was amended primarily to delay the step down of our leverage covenant from 5.50x to 5.00x until June 30, 2021.~~

~~On April 10, 2020, we used $45 million in proceeds from the sale of scil (see~~ ~~Note 3 - Divestiture and Equity Method Investment~~) to prepay our remaining quarterly principal amortization term loan payments for 2020. Following this prepayment, the next quarterly principal amortization term loan payment of $15 million is due on March 31, 2021.

~~8. Derivatives and Financial Instruments~~

We are exposed to the impact of changes in interest rates in the normal course of business. Our financial risk management program is designed to manage the exposure arising from this cash flow risk and uses derivative financial instruments to minimize this risk. We do not enter into derivative financial instruments for trading or speculative purposes.

In 2019, we executed interest rate swap contracts with notional amounts aggregating $500 million that are designated as cash flow hedges to manage interest rate risk on our floating rate debt. These interest rate swap contracts effectively fix the borrowing rates on a portion of our floating rate debt discussed in ~~Note 7 - Long-term Debt and Other Borrowings, Net~~.

Our interest rate swap agreements exchange payment streams based on the notional principal amount. These agreements fix our future interest rates ranging from 1.63% to 1.70% plus the applicable margin as provided in our debt agreement on an amount of our debt principal equal to the then-outstanding swap notional amount. The base notional amount matures on July 31, 2021. On the interest rate swap inception dates, we designated the swaps as a hedge of the variability in cash flows we pay on our variable rate borrowings.


Covetrus, Inc. 2021 Q1 Form 10-Q			12

Table of Contents

COVETRUS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In millions) (Unaudited)

~~The following table discloses the fair value~~Contract Assets and ~~balance sheet location of our derivative instruments:~~

Liability Derivatives
Cash Flow Hedging Instruments Balance Sheet Location June 30, 2020 December 31, 2019
Interest rate swap contracts Other liabilities $ 8 $ 1
Contract Liabilities

~~At inception~~Contract asset balances as of March 31, 2021 and December 31, 2020 were not material. There have been no material changes in our current portion of contract liabilities since the ~~hedging~~end of fiscal year 2020, and the amounts related to non-current contract ~~we used statistical regression to assess the effectiveness~~liabilities were not material as of ~~the interest rate hedges. The hedging contracts were deemed highly effective~~March 31, 2021 and ~~are~~December 31, 2020. See Note 1 - Business Overview and Significant Accounting Policies and Note 5 - Revenue from Contracts with Customers of our Form 10-K.

Performance Obligations

Estimated future revenues expected to be ~~highly effective throughout the hedge period. Therefore, we perform a qualitative assessment~~generated from our long-term contracts with unsatisfied performance obligations as of ~~the hedge effectiveness at each subsequent quarterly reporting date. As of June 30, 2020, derivative gains and losses~~March 31, 2021 were ~~reported as a component of Other comprehensive~~not material.

4. EARNINGS (LOSS) PER SHARE

EPS is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. In addition, the shares of common stock issuable pursuant to restricted stock awards, restricted stock units, performance stock units, and ~~will subsequently be recorded~~stock options outstanding under our 2019 Omnibus Incentive Compensation Plan and shares issuable under our Employee Stock Purchase Plan are included in the ~~condensed consolidated statements of operations when~~diluted EPS calculation to the ~~hedged transaction is recognized in earnings.~~extent they are dilutive.

The ~~effect~~following is a reconciliation of ~~cash flow hedges on Other comprehensive~~the numerator and denominator of the basic and diluted EPS computation for net income (loss) ~~was as follows:~~per share:

Cash Flow Hedging Instruments Location Three Months Ended
June 30, 2020 Six Months Ended
June 30, 2020
Amounts recognized in Other comprehensive income (loss), net of tax Accumulated other comprehensive loss $ 1 $ (7)


	Three Months Ended March 31,
(In millions, except per share amounts)		2021		2020
Numerator:






Net income (loss) available to common shareholders		$	(16)	$	(33)

Denominator:
Basic
Weighted-average common shares outstanding		136		112
Diluted
Effect of dilutive shares		0		0
Weighted-average common shares outstanding		136		112

Earnings (loss) per share attributable to Covetrus:
Basic		$	(0.11)	$	(0.30)
Diluted		$	(0.11)	$	(0.30)

Potentially dilutive securities (a)		6		7

(a) Potentially dilutive securities attributable to outstanding stock options, restricted stock units, restricted stock awards, and performance stock units were excluded from the computation of diluted earnings per share because the securities would have had an antidilutive effect

The net amount of deferred losses on cash flow hedges that are expected to be reclassified from Accumulated other comprehensive income (loss) into Interest expense within the next 12 months is $8 million.

~~9. Fair Value~~5. COMMITMENTS AND CONTINGENCIES

We are involved in various legal proceedings that arise in the ordinary course of business. Substantial judgment is required in predicting the outcome of these legal proceedings, many of which take years to adjudicate. We accrue estimated costs for a contingency when we believe that a loss is probable and can be reasonably estimated. Legal fees are expensed as incurred. No material accrued loss contingencies were recorded as of March 31, 2021.


Covetrus, Inc. 2021 Q1 Form 10-Q			13

Table of Contents

COVETRUS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In millions) (Unaudited)

Securities Litigation Matter

On September 30, 2019, the City of Hollywood (Florida) Police Officers' Retirement System filed a putative securities class action lawsuit in the United States District Court for the Eastern District of New York, purportedly on behalf of purchasers of Covetrus common stock from February 8, 2019 through August 12, 2019, against the Defendants. The complaint alleges that the Defendants violated Sections 10(b) and 20(a) of the Exchange Act, by making allegedly false and misleading statements and omissions, primarily regarding the Company’s financial prospects and the integration costs relating to the business combination involving the Animal Health Business and Vets First Choice. The suit seeks unspecified damages, fees, interest, and costs. We intend to defend the matter vigorously and have filed a motion to dismiss the lawsuit. Given the uncertainty of litigation, the preliminary stage of the case, and the legal standards that must be met for, among other things, class certification and success on the merits, we cannot estimate the reasonably possible loss or range of loss that may result from this action.

Purchase Obligations

We are party to an exclusive supply arrangement for certain products within the U.S. market until 2025 with an aggregate remaining value of $34 million. Our unconditional purchase obligation for 2021 is $8 million. For the three months ended March 31, 2021, we paid $2 million for products purchased under this exclusive arrangement. Our forecasted sales for products under this exclusive supply arrangement exceed our purchase obligations.

In 2019, we engaged a third-party for services over a three-year period ending December 31, 2022. We considered the contract to be of a “take-or-pay” nature due to the termination fees embedded in the contract: fixed termination fees of $12 million until mid-November 2020 and $14 million thereafter, plus any variable performance fees through termination. The fixed portion of the contract was capped at $14 million while the variable portion of the contract was capped at $39 million over the term of the engagement. In April 2021, we amended this contract with the third-party service provider such that the terms of the original agreement were deemed fully satisfied by both parties. In connection with the contract amendment, we agreed to pay the third party $10 million for specific services to be performed throughout the remainder of 2021. This amendment resulted in a decrease of $18 million from the remaining commitments under the original terms of the agreement.

6. INCOME TAXES

Income tax expense for the three months ended March 31, 2021 was $4 million on a loss before taxes and equity in earnings of affiliates of $12 million. The difference between our tax expense and the tax expense using the statutory tax rates for the jurisdictions in which we operate, for this period, primary related to valuation allowances due to uncertainty regarding the realization of future tax benefits from certain U.S. deferred tax assets.

Income tax benefit for the three months ended March 31, 2020 was $2 million on a loss before taxes and equity in earnings of affiliates of $35 million. The difference between our tax expense and the tax expense using the statutory tax rates for the jurisdictions in which we operate, for this period, primarily related to valuation allowances due to uncertainty regarding the realization of future tax benefits from certain U.S. deferred tax assets and non-deductible expenses associated with share-based compensation.

7. FAIR VALUE

GAAP defines fair value as the price that would be received from the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

We have certain financial assets and liabilities that are measured at fair value on a recurring basis, certain nonfinancial assets and liabilities that may be measured at fair value on a non-recurring basis, and certain financial assets and liabilities that are not measured at fair value in our condensed consolidated balance sheets, but the fair value is disclosed. The fair value disclosures of these assets and liabilities are based on a three-level hierarchy, which is defined as follows:

•Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities


Covetrus, Inc. 2021 Q1 Form 10-Q			14

Table of Contents

COVETRUS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In millions) (Unaudited)

•Level 2 - Unadjusted quoted prices in active markets for similar assets or liabilities, or unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable for the asset or liability

•Level 3 - Unobservable inputs for the asset or liability

There were no changes in valuation approaches or techniques during the three ~~and six~~ months ended ~~June 30, 2020.~~March 31, 2021. See Note 911 - Fair Value in our Form 10-K for a description of our valuation techniques.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table presents our financial instruments measured at fair value on a recurring basis and indicates the level within the fair value hierarchy:

Level June 30, 2020 December 31, 2019
Liabilities:
Interest rate swap contracts 2 $ 8 $ 1
Distrivet put option 3 5 —
Total liabilities $ 13 $ 1


Assets	Level	March 31, 2021		December 31, 2020
Distrivet call option	3	$	2	$	2
Total assets		$	2	$	2


Liabilities	Level	March 31, 2021		December 31, 2020





Interest rate swap contracts	2	$	3	$	5
Distrivet put option	3	1		1
Total liabilities		$	4	$	6

~~Table of Contents~~

~~COVETRUS, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(In millions) (Unaudited)~~

Interest Rate Swap Contracts

Our derivatives at ~~June 30, 2020~~March 31, 2021 consisted of 5 interest rate swap contracts which are over-the-counter and not traded through an exchange. The fair values of our swap contracts are determined based on inputs that are readily available in public markets or can be derived from information available in publicly quoted markets. These interest rate swap contracts mature on July 31, 2021. See Note 8 - Derivatives ~~and Financial Instruments~~.

Distrivet ~~Put Option~~Options

The Distrivet ~~put option~~options fair value was derived from a Monte Carlo simulation methodology. The significant unobservable inputs utilized in this Level 3 fair value measurement includes the enterprise value of Distrivet ($156 million), volatility (30%), and cost of ~~debt.~~capital (15%). We regularly evaluate each of the assumptions used in establishing ~~this~~the asset and liability. Significant changes in assumptions could result in significantly lower or higher fair value measurements. ~~See~~ ~~Note 3 - Divestiture and Equity Method Investment.~~

Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis

Assets that are measured at fair value on a nonrecurring basis primarily relate to Property and equipment, net, Operating lease right-of-use assets, net, Goodwill, and Other intangibles, net. We do not periodically adjust carrying value to fair value for these assets; rather, the carrying value of the asset is reduced to its fair value when we determine that impairment has occurred. We did not have any assets or liabilities measured at fair value on a nonrecurring basis during the ~~six~~three months ~~ended June 30, 2020 or the year ended December~~ending March 31, ~~2019.~~2021.

Assets and Liabilities ~~not~~Not Measured at Fair Value

Financial Assets and Liabilities

The carrying amounts reported on the condensed consolidated balance sheets for Cash and cash equivalents, Accounts receivable, net, Other receivables, Accounts payable, and accrued expenses approximate their fair value due to the short maturity of those instruments.

~~Investments in Affiliates~~

~~There are no quoted market prices available for investments in affiliates, however, we believe the carrying amounts are a reasonable estimate of fair value.~~

Long-term Debt

Our long-term debt is classified as a level 2 instrument. The carrying amount of the term loan approximates fair value given the underlying interest rate applied to such amounts outstanding ~~and~~ is currently reset to the prevailing monthly market rate.

~~10. Commitments and Contingencies~~

We are involved in various legal proceedings that arise in the ordinary course of business. Substantial judgment is required in predicting the outcome of these legal proceedings, many of which take years to adjudicate. We accrue estimated costs for a contingency when we believe that a loss is probable and can be reasonably estimated. No material accrued loss contingencies were recorded as of June 30, 2020.

~~Securities Litigation Matter~~

On September 30, 2019, the City of Hollywood (Florida) Police Officers' Retirement System filed a putative securities class action lawsuit in the United States District Court for the Eastern District of New York, purportedly on behalf of purchasers of Covetrus common stock from February 8, 2019 through August 12, 2019, against the Company, our Former Parent, our former Chief Executive Officer and President, and our former Chief Financial Officer (collectively, the “Defendants”). The complaint alleges that the Defendants violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), by making allegedly false and misleading statements and omissions, primarily regarding the Company’s financial prospects and the integration costs relating to the business combination involving the Animal Health Business and Vets First Choice. The suit seeks unspecified damages, fees, interest, and costs. We intend to defend the matter vigorously and have filed a motion to dismiss the lawsuit. Given the uncertainty of litigation, the preliminary stage of the case, and the legal standards that must be met


Covetrus, Inc. 2021 Q1 Form 10-Q			15

Table of Contents

COVETRUS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In millions) (Unaudited)

~~for, among other things, class certification and success on the merits, we cannot estimate the reasonably possible loss or range of loss that may result from this action.~~

~~Purchase Obligations~~

8. DERIVATIVES

We are ~~party~~exposed to the impact of changes in interest rates in the normal course of business. Our financial risk management program is designed to manage the exposure arising from this cash flow risk and uses derivative financial instruments to minimize this risk. We do not enter into derivative financial instruments for trading or speculative purposes.

In July and August 2019, we executed interest rate swap contracts with notional amounts aggregating $500 million that are designated as cash flow hedges to manage interest rate risk on our floating rate debt. These interest rate swap contracts effectively fix the borrowing rates on a portion of our floating rate debt. The base notional amounts mature on July 31, 2021. On the interest rate swap inception dates, we designated the swaps as a hedge of the variability in cash flows we pay on our variable rate borrowings.

Our interest rate swap agreements exchange payment streams based on the notional principal amount. These agreements fix our future interest rates ranging from 1.63% to 1.70% plus the applicable margin as provided in our debt agreement on an ~~exclusive supply arrangement for certain products within~~amount of our debt principal equal to the U.S. market. We amended this arrangement in February 2020 to extend the purchase obligations until 2025 which include unconditional purchase obligations totaling $44 million over this period. Our unconditional purchase obligations for 2020 is $8 million. During the six months ended June 30, 2020, we paid $4 million for products purchased under this exclusive arrangement, leaving a remaining commitment of $40 million. Our forecasted sales for products under this exclusive supply arrangement exceed our purchase obligations.then-outstanding swap notional amount.

~~In 2019, we engaged a third-party for services over a three-year period ending December 31, 2022.~~ The ~~fixed portion~~following table discloses the fair value and balance sheet location of our derivative instruments:

Liability Derivatives

Cash Flow Hedging Instruments

Balance Sheet Location

March 31, 2021

December 31, 2020

Interest rate swap contracts

Other liabilities

At inception of the hedging contract, ~~is capped at $14 million while~~we used statistical regression to assess the ~~variable portion~~effectiveness of the ~~contract is capped at $39 million over~~interest rate hedges. The hedging contracts were deemed highly effective and are expected to be highly effective throughout the ~~term~~hedge period. Therefore, we perform a qualitative assessment of the ~~engagement. We consider~~hedge effectiveness at each subsequent quarterly reporting date. As of March 31, 2021, derivative gains and losses were reported as a component of Other comprehensive income (loss) and will subsequently be recorded in the ~~contract~~condensed consolidated statements of operations when the hedged transaction is recognized in earnings.

The effect of cash flow hedges on Other comprehensive income (loss) was as follows:



		Three Months Ended March 31,
Cash Flow Hedging Instruments	Location		2021		2020

Interest rate swap contracts	Interest (income) expense		$	2	$	0

The net amount of deferred losses on cash flow hedges that are expected to be ~~of a “take-or-pay” nature due to~~reclassified from Accumulated other comprehensive income (loss) into Interest expense within the termination fees embedded in the contract: fixed termination fees of $12 million until mid-November 2020 and $14 million thereafter, plus any variable performance fees through termination. During 2019, we incurred $2 million in fixed fees. During the sixnext 12 months ~~ended June 30, 2020, we incurred $7 million in variable fees and $2 million in fixed fees under this arrangement, leaving a remaining potential commitment of $42~~is $3 million.

~~11. Redeemable Non-controlling Interests~~


Covetrus, Inc. 2021 Q1 Form 10-Q			16

Table of Contents

COVETRUS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In millions) (Unaudited)

9. ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)

The following table presents the changes in Accumulated other comprehensive loss, net of applicable taxes, by component:


	Derivative Gain (Loss)		Foreign Currency Translation Gain (Loss)		Total
Balance at December 31, 2019	$	0	$	(86)	$	(86)
Other comprehensive loss before reclassifications	(8)		(22)		(30)
Reclassified from Accumulated other comprehensive loss to earnings	0		0		0
Period Change	(8)		(22)		(30)
Balance at March 31, 2020	(8)		(108)		(116)

Balance at December 31, 2020	$	(3)	$	(63)	$	(66)
Other comprehensive loss before reclassifications	0		(11)		(11)
Reclassified from Accumulated other comprehensive loss to earnings	2		0		2
Period Change	2		(11)		(9)
Balance at March 31, 2021	$	(1)	$	(74)	$	(75)

Comprehensive income (loss) includes certain gains and losses that are excluded from Net income (loss) under GAAP as these amounts are recorded directly as an adjustment to total equity. We recognize foreign currency translation losses as a component of comprehensive income (loss) due to changes in foreign exchange rates from the beginning of the period to the end of the period. The condensed consolidated financial statements are denominated in the U.S. dollar. Fluctuations in the value of foreign currencies as compared to the U.S. dollar may have a significant impact on Comprehensive income (loss).

The tax effect on accumulated unrealized losses on derivative instruments was not material for the periods presented. See Note 8 - Derivatives.

10. REDEEMABLE NON-CONTROLLING INTERESTS

Some minority equity owners in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities. We initially record our Redeemable non-controlling interests at fair value on the date of acquisition and subsequently adjust to redemption value.

The following table presents the components of change and balances of Redeemable non-controlling interests within the condensed consolidated balance sheets as follows:

Six Months Ended June 30, 2020 Year Ended
December 31, 2019
Balance at beginning of period $ 10 $ 92
Decrease due to redemptions — (74)
Net income (loss) attributable to redeemable non-controlling interests 1 (3)
Effect of foreign currency translation (gain) loss attributable to redeemable non-controlling interests (2) 1
Change to redemption value — (6)
Balance at end of period $ 9 $ 10

~~12. Redeemable Series A Convertible Preferred Stock~~

On May 19, 2020, we issued 250,000 shares of our 7.5% Series A Convertible Preferred Stock (the “Series A Preferred Stock”), with a par value of $0.01 per share, for an aggregate purchase price of $250 million, or $1,000 per share, pursuant to an Investment Agreement (the “Investment Agreement”) with CD&R VFC Holdings, L.P. (the “Purchaser”), an affiliate of Clayton, Dubilier��& Rice, LLC, dated April 30, 2020. We received net proceeds of $244 million after issuance costs, a portion of which was used to pay down our revolver borrowings and the remainder of which will be used to provide additional short-term liquidity and support general corporate purposes.

~~Our Series A Preferred Stock is a participating security for our calculation of earnings per share (see~~ ~~Note 15 - Earnings (Loss) Per Share). Below is a summary of our Series A Preferred Stock characteristics, which are set forth in the Certificate of Designations:~~

~~Voting and Other~~

The holders of our Series A Preferred Stock vote together with the holders of common stock as a single class on an as-converted basis. In addition, the holders are entitled to vote as a separate class on certain matters and as required by law.


	Three Months Ended March 31, 2021		Year Ended December 31, 2020
Balance at beginning of period	$	36	$	10
Decrease due to redemptions	0		(4)
Increase due to business acquisitions	0		24
Net income (loss) attributable to redeemable non-controlling interests	0		2

Effect of foreign currency translation (gain) loss attributable to redeemable non-controlling interests	(1)		(2)
Change to redemption value	1		6
Balance at end of period	$	36	$	36

~~Table of Contents~~

~~COVETRUS, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(In millions) (Unaudited)~~

On an as-converted basis, together with the Purchaser's existing common shares of Covetrus, the Purchaser owns approximately 25% of pro forma common shares outstanding. However, unless certain stockholder approval is obtained, the terms of the Series A Preferred Stock limit the Purchaser's voting interest to 19.99% of our then-outstanding voting interests.

~~Under the terms of the Investment Agreement, the Purchaser has the right to appoint 2 designees to our board of directors.~~

~~Dividends~~

The holders participate in dividends on an as-converted basis when paid on common stock. Additionally, the holders are entitled to cumulative dividends, payable quarterly in arrears, at an annual rate of 7.5% of the stated value of $1,000 per share. Dividends may be paid in cash or accrue in accordance with the terms of the Certificate of Designations. For the three months ended June 30, 2020, our board of directors declared a pro rata quarterly dividend of $8.65 per share, or $2 million, that was paid on June 30, 2020. Accordingly, there were no cumulative dividends included in the accompanying condensed consolidated financial statements in connection with the outstanding shares of Series A Preferred Stock.

~~Conversion Rights~~

At the option of the holder, each share of the Series A Preferred Stock is convertible into common stock at any time as is determined by dividing the applicable conversion value by the applicable conversion price in effect at the time of conversion.

At the option of the Company, we may require the conversion of all of the outstanding shares of Series A Preferred Stock into the relevant number of shares of our common stock if either (i) our consolidated EBITDA (as defined in the Certificate of Designations) exceeds $300 million for 2 consecutive 12-month periods and our consolidated net total leverage ratio (as defined in the Certificate of Designations) as of the last day of such 2 consecutive 12-month periods does not exceed 4:00:1:00, or (ii) the volume-weighted average price of our common stock exceeds the product of the mandatory conversion threshold, 200%, if within two years of the issuance date multiplied by the conversion price on each of at least 20 trading days (whether or not consecutive) in a period of 30 consecutive trading days. Currently, our conversion price as described under (ii) above is $22.20.

However, unless certain stockholder approval is obtained, no share of Series A Preferred Stock is convertible into common stock if the conversion would result in the holder beneficially owning more than 19.99% of our then outstanding voting power.

In determining the appropriate classification for the conversion features of the Series A Preferred Stock, we determined that the conversion features do not meet the definition of a derivative and that bifurcation was not required as the features are considered clearly and closely related to the host instruments.

~~Redemption Provision~~

At the option of the holder, upon certain change in control events, each share of the Series A Preferred Stock is redeemable in an amount in cash equal to 101% of the liquidation preference thereof plus all accrued and unpaid dividends. Should the holders not redeem, we have the option to redeem the shares, upon certain change of control events, in an amount in cash equal to the liquidation preference as of the date of redemption, plus all accrued but unpaid dividends as of the date of redemption, plus certain additional amounts if the applicable redemption date is prior to the fifth anniversary of the date of issuance of such Series A Preferred Stock. As of June 30, 2020, a change in control was not probable.

~~We determined that bifurcation of the redemption features was not required as they do not require net settlement and therefore do not meet the definition of a derivative.~~

~~Liquidation Rights~~

In the event of any voluntary or involuntary liquidation, dissolution, or winding up of Covetrus, the holders of outstanding shares of Series A Preferred Stock are entitled to be paid out of the assets of Covetrus available for distribution to our shareholders before any payment to the holders of our common stock.

~~Table of Contents~~

~~COVETRUS, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(In millions) (Unaudited)~~

~~13. Accumulated Other Comprehensive Income (Loss)~~

~~Comprehensive income (loss) includes certain gains and losses that are excluded from net income (loss) under GAAP as these amounts are recorded directly as an adjustment to total equity.~~

~~The following table presents the changes in Accumulated other comprehensive loss, net of applicable taxes, by component:~~

Derivative Loss Foreign Currency Translation Loss Total
Balance at December 29, 2018 $ — $ (82) $ (82)
Other comprehensive loss before reclassifications (1) (4) (5)
Reclassified from Accumulated other comprehensive loss to earnings 1 — 1
Balance at December 31, 2019 — (86) (86)
Other comprehensive loss before reclassifications (7) (16) (23)
Reclassified from Accumulated other comprehensive loss to earnings — 2 2
Balance at June 30, 2020 $ (7) $ (100) $ (107)

We recognized foreign currency translation losses as a component of comprehensive income (loss) due to changes in foreign exchange rates from the beginning of the period to the end of the period. The condensed consolidated financial statements are denominated in the U.S. dollar currency. Fluctuations in the value of foreign currencies as compared to the U.S. dollar may have a significant impact on Comprehensive income (loss).

~~The tax effect on accumulated unrealized losses on derivative instruments was not material for the periods presented. See~~ ~~Note 8 - Derivatives and Financial Instruments~~.

~~14. Income Taxes~~

Income tax expense for the three months ended June 30, 2020 was $6 million on income before taxes and equity in earnings of affiliates of $59 million for a consolidated effective tax rate of 10.6%. The difference between our effective tax rate and the statutory tax rates for the jurisdictions in which we operate for the three months ended June 30, 2020, primarily related to valuation allowances due to uncertainty regarding the realization of future tax benefits from deferred tax assets and the sale of scil business units.

Income tax expense for the six months ended June 30, 2020 was $4 million on income before taxes and equity in earnings of affiliates of $24 million for a consolidated effective tax rate of 17.7%. The difference between our effective tax rate and the federal statutory tax rates for the jurisdictions in which we operate for the six months ended June 30, 2020, primarily related to non-deductible share-based compensation expense, the sale of scil business units, valuation allowances due to uncertainty regarding the realization of future tax benefits from deferred tax assets, and the federal tax impact of international operations included as Global Intangible Low-Taxed Income (“GILTI”).

Income tax expense for the three months ended June 30, 2019 was $5 million on a loss before taxes and equity in earnings of affiliates of $5 million for a consolidated effective tax rate of (94.8)%. The difference between our effective tax rate and the statutory tax rates for the jurisdictions in which we operate for the three months ended June 30, 2019, primarily related to the change from using the actual effective tax rate methodology for the three months ended March 31, 2019 to an annualized effective tax rate methodology for the three and six months ended June 30, 2019.

Income tax expense for the six months ended June 30, 2019 was $1 million on a loss before taxes and equity in earnings of affiliates of $22 million for a consolidated effective tax rate of (2.4)%. The difference between our effective tax rate and the federal statutory tax rates for the jurisdictions in which we operate for the six months ended June 30, 2019, primarily related to the federal tax impact of international operations included as GILTI and non-deductible share-based compensation expense.

~~Table of Contents~~

~~COVETRUS, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(In millions) (Unaudited)~~

~~The CARES Act~~

On March 27, 2020, the President of the United States signed the CARES Act, a substantial tax-and-spending package intended to provide additional economic stimulus to address the impact of the COVID-19 pandemic. The CARES Act did not have a material impact on our condensed consolidated financial statements as of and for the three and six months ended June 30, 2020.

~~15. Earnings (Loss) Per Share~~

Basic earnings (loss) per common share (“EPS”) is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. In addition, the shares of common stock issuable pursuant to restricted stock awards, restricted stock units, performance stock units, and stock options outstanding under our 2019 Omnibus Incentive Compensation Plan, shares issuable under our Employee Stock Purchase Plan, and Series A~~Preferred Stock are included in the diluted EPS calculation to the extent they are dilutive.~~

~~The following is a reconciliation of the numerator and denominator of the basic and diluted EPS computation for net income (loss) per share:~~

Three Months Ended June 30, Six Months Ended June 30,
(In millions, except per share amounts) 2020 2019 2020 2019
Numerator:
Net income (loss) attributable to Covetrus $ 54 $ (10) $ 20 $ (23)
Adjustment for:
Dividends declared on Series A Preferred Stock (2) — (2) —
Allocation of earnings to participating securities (6) — (1) —
Income (loss) available to common shareholders $ 46 $ (10) $ 17 $ (23)
Denominator:
Basic
Weighted-average common shares outstanding 112 112 112 103
Diluted
Effect of dilutive shares 1 — 1 —
Weighted-average common shares outstanding 113 112 113 103
Income (loss) per share attributable to Covetrus:
Basic $ 0.40 $ (0.09) $ 0.15 $ (0.22)
Diluted $ 0.40 $ (0.09) $ 0.15 $ (0.22)
Potentially dilutive securities^(a)
19 5 12 3
(a) Potentially dilutive securities attributable to outstanding convertible Series A Preferred Stock, stock options, restricted stock units, and restricted stock awards were excluded from the computation of diluted earnings per share because the securities would have had an antidilutive effect.

~~16. Share-based Compensation~~

~~Share-based Compensation Expense~~

In connection with share-based payment awards, we recorded share-based compensation expense of $10 million for the three months ended June 30, 2020, $10 million for the three months ended June 30, 2019, $19 million for the six months ended June 30, 2020, and $25 million for the six months ended June 30, 2019 which is included in Selling, general and administrative within the condensed consolidated statements of operations. As of June 30, 2020, there was $72 million in unrecognized compensation expense related to nonvested share-based awards that is expected to be recognized over a weighted-average period of 2.0 years.

~~Table of Contents~~

~~COVETRUS, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(In millions) (Unaudited)~~

~~Performance-based Grants~~

Under our 2019 Omnibus Incentive Compensation Plan (the “Plan”), we grant restricted stock awards that are subject to performance conditions to certain participating employees. For the six months ended June 30, 2020, we granted 1,323,267 performance stock units (“PSUs”) under the Plan with a weighted-average fair value of $11.34. The performance stock units are subject to the specific performance conditions, vesting on a one-year performance cycle. Compensation expense for the PSUs for the three months ended June 30, 2020 was $1 million, which is included in share-based compensation expense noted above.

~~17. Related Party Transactions~~

~~Upon closing the transaction with Distrivet, S.A. on April 30, 2020 (see~~ ~~Note 3 - Divestiture and Equity Method Investment~~), Distrivet, our equity method investee, became a related party. During the three months ended June 30, 2020, we provided management services and corporate branding to Distrivet under our agreement, and we provided goods to Distrivet. These services and product sales were not material during this period.

~~18. Segment Data~~

~~The following tables reflect our segment and Corporate information and reconciles Adjusted EBITDA for reportable segments to consolidated Net income (loss) attributable to Covetrus:~~

At and For the Three Months Ended June 30, 2020
North America Europe APAC & Emerging Markets Corporate Eliminations Total
Net sales $ 602 $ 342 $ 85 $ — $ (3) $ 1,026
Adjusted EBITDA $ 55 $ 16 $ 5 $ (13) $ — $ 63
Total assets $ 3,066 $ 635 $ 132 $ 1,145 $ (1,452) $ 3,526
Reconciliation of net income Attributable to Covetrus to Adjusted EBITDA:
Net income attributable to Covetrus $ 54
Plus: Depreciation and amortization 41
Plus: Interest expense, net 13
Plus: Income tax expense 6
Earnings before interest, taxes, depreciation, and amortization 114
Plus: Share-based compensation 10
Plus: Strategic consulting 5
Plus: Separation programs and executive severance 1
Plus: Formation of Covetrus^(a)
7
Plus: Capital structure 1
Less: Other income items, net^(b)
(75)
Adjusted EBITDA $ 63
(a) Includes professional and consulting fees, duplicative costs associated with transition service agreements, and other costs incurred in connection with the separation from Former Parent and establishing Covetrus as an independent public company.
(b) Includes a $73 million gain on the divestiture of scil and a $1 million gain on the deconsolidation of SAHS. See Note 3 - Divestiture and Equity Method Investment.

~~Table of Contents~~

~~COVETRUS, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(In millions) (Unaudited)~~

At and For the Three Months Ended June 30, 2019
North America Europe APAC & Emerging Markets Corporate Eliminations Total
Net sales $ 552 $ 370 $ 90 $ — $ (3) $ 1,009
Adjusted EBITDA $ 43 $ 19 $ 4 $ (13) $ — $ 53
Total assets $ 3,265 $ 797 $ 191 $ 872 $ (935) $ 4,190
Reconciliation of net loss Attributable to Covetrus to Adjusted EBITDA:
Net loss attributable to Covetrus $ (10)
Plus: Depreciation and amortization 41
Plus: Interest expense, net 14
Plus: Income tax expense 5
Earnings before interest, taxes, depreciation, and amortization 50
Plus: Share-based compensation 10
Plus: Formation of Covetrus^(a)
6
Plus: IT infrastructure 2
Less: Other income items, net (15)
Adjusted EBITDA $ 53
(a) Includes professional and consulting fees, duplicative costs associated with transition service agreements, and other costs incurred in connection with the separation from Former Parent and establishing Covetrus as an independent public company.

~~Table of Contents~~

~~COVETRUS, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(In millions) (Unaudited)~~

For the Six Months Ended June 30, 2020
North America Europe APAC & Emerging Markets Corporate Eliminations Total
Net sales $ 1,152 $ 764 $ 180 $ — $ (5) $ 2,091
Adjusted EBITDA $ 96 $ 34 $ 12 $ (31) $ — $ 111
Reconciliation of net income Attributable to Covetrus to Adjusted EBITDA:
Net income attributable to Covetrus $ 20
Plus: Depreciation and amortization 82
Plus: Interest expense, net 27
Plus: Income tax expense 4
Earnings before interest, taxes, depreciation, and amortization 133
Plus: Share-based compensation 19
Plus: Strategic consulting 9
Plus: Transaction costs^(a)
6
Plus: Separation programs and executive severance 2
Plus: IT infrastructure 2
Plus: Formation of Covetrus^(b)
14
Plus: Capital structure 1
Less: Other income items, net^(c)
(75)
Adjusted EBITDA $ 111
(a) Includes legal, accounting, tax, and other professional fees incurred in connection with acquisitions and divestitures.
(b) Includes professional and consulting fees, duplicative costs associated with transition service agreements, and other costs incurred in connection with the separation from Former Parent and establishing Covetrus as an independent public company.
(c) Includes a $73 million gain on the divestiture of scil and a $1 million gain on the deconsolidation of SAHS. See Note 3 - Divestiture and Equity Method Investment.

~~Table of Contents~~

~~COVETRUS, INC.~~

~~NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS~~

~~(In millions) (Unaudited)~~

For the Six Months Ended June 30, 2019
North America Europe APAC & Emerging Markets Corporate Eliminations Total
Net sales $ 1,049 $ 731 $ 176 $ — $ (6) $ 1,950
Adjusted EBITDA $ 78 $ 35 $ 8 $ (16) $ — $ 105
Reconciliation of net loss Attributable to Covetrus to Adjusted EBITDA:
Net loss attributable to Covetrus $ (23)
Plus: Depreciation and amortization 71
Plus: Interest expense, net 25
Plus: Income tax expense 1
Earnings before interest, taxes, depreciation, and amortization 74
Plus: Share-based compensation 25
Plus: Formation of Covetrus^(a)
14
Plus: Carve-out operating expenses 5
Plus: IT infrastructure 2
Less: Other income items, net (15)
Adjusted EBITDA $ 105
(a) Includes professional and consulting fees, duplicative costs associated with transition service agreements, and other costs incurred in connection with the separation from Former Parent and establishing Covetrus as an independent public company.

~~See~~ ~~Note 4 - Revenue from Contracts with Customers~~ ~~for our revenue disaggregated by major product category and reportable segment.~~


Covetrus, Inc. 2021 Q1 Form 10-Q			17

Table of Contents

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-looking Statements

Certain matters discussed in this ~~Quarterly Report on~~ Form 10-Q, ~~(“Form 10-Q” or “Report”),~~ and in particular, this management’s discussion and analysis of financial condition and results of operations, contain statements, estimates, and projections that are “forward-looking statements” as defined under U.S. federal securities laws and involve substantial risks and uncertainties. When used in this Report, the words “anticipate,” “assume,” “believe,” “budget,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “future,” and the negative of these or similar terms and phrases are intended to identify forward-looking statements. Such statements are subject to numerous risks and uncertainties, and actual results could differ materially from those anticipated due to a number of factors including but not limited to:

•the effect of health epidemics, including the COVID-19 pandemic, on our business and the success of any measures we have taken or may take in the future in response thereto, including our ability to continue operations at our distribution centers and pharmacies

•~~risks associated with our management transition~~

•the ability to successfully integrate operations and employees

•the ability to ~~realize anticipated benefits and synergies of the transactions that created Covetrus~~

•~~the potential impact of the consummation of the transactions~~continue to execute on ~~relationships, including with employees, customers, and competitors~~our strategic plan

•the ability to retain key personnel

•the ability to achieve performance targets, including managing our growth effectively

•the ability to manage relationships with our supplier and distributor network, including negotiating acceptable pricing and other terms with these partners

•the ability to attract and retain customers in a price sensitive environment

•the ability to maintain quality standards in our technology product offerings as well as associated customer service interactions to minimize loss of existing Customers and attract new Customers

•changes in financial markets, interest rates, and foreign currency exchange rates

•changes in the legislative landscape in which we operate, including potential corporate tax reform, and our ~~market~~ability to adapt to those changes as well as adaptation by the third-parties we are dependent upon for supply and distribution

•the impact of litigation

•~~the impact of Brexit~~

•the impact of accounting pronouncements, seasonality of our business, leases, expenses, interest expense, and debt

•sufficiency of cash and access to liquidity

•cybersecurity risks, including risk associated with our dependence on third-party service providers as a large portion of our workforce is working from home

•additional risks and factors discussed ~~including those discussed~~ under the heading ~~“Risk Factors”~~Risk Factors in this Report, ~~and~~ in our Form 10-K filed on March ~~3, 2020,~~1, 2021, and in our other SEC filings

Our forward-looking statements are based on current beliefs and expectations of our management team and, except as required by law, we undertake no obligations to make any revisions to the forward-looking statements contained in this Report or to update them to reflect events or circumstances occurring after the date of this Report, whether as a result of new information, future developments, or otherwise.

Although we believe the expectations reflected in the forward-looking statements are reasonable, we can give no assurance that these expectations will prove to have been correct. These expectations may or may not be realized. Some of these expectations may be based upon assumptions, data, or judgments that prove to be incorrect. Actual events, results, and outcomes may differ materially from our expectations due to a variety of known and unknown risks, uncertainties, and other factors. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include those set forth in this Form 10-Q and under the caption Item 1A. Risk Factors in our Form 10-K.

We operate in a very competitive and rapidly changing market. New risks emerge from time to time, and it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. The results of operations for the three ~~and six~~ months ended ~~June 30, 2020~~March 31, 2021 are not necessarily indicative of what our operating results for the full fiscal year will be. For the foregoing reasons, you are cautioned against relying on any forward-looking statements.

You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed consolidated financial statements and the related notes thereto appearing elsewhere in this Form 10-Q and our consolidated financial statements and the related notes and other financial information included in our Form 10-K.

~~The terms “Covetrus,” “Company,” “we,” “our,” “us,” or “ourselves” included in this Report mean Covetrus, Inc. and its consolidated subsidiaries, collectively.~~


Covetrus, Inc. 2021 Q1 Form 10-Q			18

Table of Contents

Rounding adjustments applied to individual numbers and percentages shown in this Report may result in these figures differing immaterially from their absolute values and certain tables may not foot or cross foot.

Overview

We are a global, animal-health technology and services company dedicated to supporting the companion, equine, and large-animal veterinary markets. Our mission is to provide the best products, services, and technology to veterinarians and animal-health practitioners across the globe, so they can deliver exceptional care to their patients when and where it is needed. In February 2019, we combined the complementary capabilities of the Animal Health Business, previously operated by our Former Parent, and Vets First Choice, bringing together leading practice management software and supply chain distribution businesses with a technology-enabled prescription management platform and related pharmacy services. ~~We believe our approach to the market will support the delivery of improved veterinary care and health of their practices while driving increased demand for our products and services.~~

~~Segments~~

We are organized based upon geographic region and focus on delivering our platform of products and services to our ~~customers~~Customers on a geographical ~~basis, our~~basis. Our reportable segments ~~consist of the following:~~are (i) North America, (ii) Europe, and (iii) APAC & Emerging Markets. ~~We evaluate~~Our major product groups that we disaggregate within our ~~segment profit (loss) solely based on adjusted earnings before interest, taxes, depreciation,~~reportable segments are (i) supply chain services, (ii) software services, and ~~amortization (“Adjusted EBITDA”).~~(iii) prescription management. See Note 2 - Segment Data and Note 3 - Revenue from Contracts with Customers.

~~Definition~~Across our segments and major product groups, the willingness of ~~Non-GAAP Adjusted Earnings Before Interest, Taxes, Depreciation,~~Animal Owners to spend with their veterinarians on preventative and ~~Amortization~~

~~Adjusted EBITDA~~therapeutic treatments and procedures is ~~a non-GAAP financial measure used~~critical to ~~(i) aid management and investors with year-over-year comparability, (ii) determine management performance under our compensation plans, (iii) plan and forecast, (iv) communicate~~ our financial ~~performance~~performance. In the companion-animal market specifically, there is an ongoing trend of owners humanizing, or providing the best possible lives for, their pets. Across the companion-animal, equine, and large-animal markets, we anticipate that for us to succeed on our ~~board of directors, shareholders,~~strategic roadmap, we should seek to strengthen the relationship between Customers and ~~investment analysts, and (v) understand~~Animal Owners, enable our ~~operating performance without regard~~Customers to ~~items we do not consider a component of our core ongoing operating performance. Adjusted EBITDA has certain limitations in that it does not consider the impact of certain expenses~~provide proactive healthcare options to our condensed consolidated statements of operations. Adjusted EBITDA excludes share-based compensation, strategic consulting, transaction costs, formation of Covetrus expenses, separation programs and executive severance, carve-out operating expenses, IT infrastructure, goodwill impairment charges, capital structure related fees, and other (income) expense items, net. Currently, we do not allocate expenses managed at the corporate level, such as corporate wages and related benefits, corporate occupancy costs, professional services utilized at the corporate level, and non-recurring expenses to our operating segments. Other companies may not define or calculate Adjusted EBITDA in the same way. We provide Adjusted EBITDA by segment as a supplemental measure to GAAP. See below for our Adjusted EBITDA explanations on a segment basisAnimal Owners, as well as ~~on a consolidated, non-GAAP basis. Non-GAAP Adjusted EBITDA on a total segment basis is reconciled~~invest in ~~Note 18 - Segment Data~~ ~~as required by ASC 280.~~technology solutions, proprietary brand products, and compounding.

Key Factors and Trends Affecting our Results

~~Impact~~Growth continues following the onset of the COVID-19 ~~on our Business~~

In an effort to contain COVID-19 or slow its spread, governments around the world enacted various measures, including orders to close all businesses not deemed “essential,” isolate residents to their homes or places of residence, and practice social distancing when engaging in essential activities. The determination of what is an “essential” business is mandated by local authorities. Border restrictions have been slowly easing in certain places around the world and several countries are beginning to lift lock-down measures. However, since various countries have begun to reopen, there has been a surge of coronavirus cases in various locations, and some countries are experiencing a second wave of infections. Due to the spike in cases, some regions are re-entering lockdowns, stepping up restrictions, or delaying phased re-opening plans. Operationally, all of our distribution centers and pharmacies have continued to remain open as veterinary medicine has been deemed an essential service in most geographies across the globe. Additionally, our supply chain operations continue to work with manufacturers and suppliers across the globe to provide access to critical supplies and quality products.pandemic

During 2020, the animal-health market largely benefited from the lockdowns instituted in response to the COVID-19 pandemic, including the benefit to veterinary practices, including our Customers, from an increase in visits driven by people adopting more pets during 2020 as well as companion Animal Owners increasing their per-visit spend with their veterinarians. This is expected to be a multi-year effect as these Animal Owners seek care from veterinary practices for their newly adopted pets. Additionally, the required responses to mitigate the spread of the COVID-19 pandemic shifted customer and animal-owner demand to our prescription management and online pharmacy services. However, we did not experience this COVID-19 driven growth on a straight-line basis: there was a spike in supply chain services sales in March 2020 that we consider a pull-forward effect, followed by a significant weakening of sales in April 2020 as that pull-forward effect balanced out; our growth in supply chain services and prescription management then accelerated for the remainder of the second quarter before normalizing in the third and fourth quarters. On a year-over-year basis, the surge of sales in March 2020 provided a difficult comparable for our first quarter of 2021 performance. The net sales growth in the first quarter of ~~2020,~~2021 reflects the continued resiliency of the companion- animal end-market, our improved sales execution which was furthered by our commercial organization realignment in North America as of January 1, 2021, and elevated purchasing patterns from our prescription management and online pharmacy service users continuing into 2021. The retention of Customers brought to us during the COVID-19 pandemic in 2021 and beyond, our continued market penetration, and the introduction of product and service offerings aimed at driving higher utilization post enrollment could lead to long-term net sales ~~reflected~~growth.

Foreign Currency Effects

Our performance was positively affected by the ~~positive momentum~~appreciation of other currencies as compared to the ~~business had entering~~U.S. dollar in the first quarter of 2021 as compared to the first quarter of 2020. However, this effect may be temporary.

Investing in Innovation and Corporate Infrastructure

During 2020, ~~benefiting from prescription management growth and~~we undertook certain ~~inventory stocking activity in several geographies in connection with~~temporary cost-containment measures to help us manage the uncertainty created by the COVID-19 ~~pandemic. A resurgence of COVID-19 may result in a reduction in our companion animal-related net sales~~pandemic as ~~wellness-related veterinary practice visits may decline; the companion-animal market represent approximately 75% of our global supply chain net sales. From mid-March to the end of April, we~~well as experienced a ~~significant slowdown~~continuing beneficial effect on our SG&A from decreased travel and in-person trade shows and conferences. Those cost-cutting measures we instituted in ~~net sales as some markets, such as Spain, went into a stricter lockdown. As a result~~2020 are still lowering certain SG&A items in the first quarter of ~~this slowdown~~2021. However, we continue to spend on our corporate functions to build out the structure necessary to support our business today. Our strategic initiatives in the near and long-term are focused on accelerating the ~~uncertainty surrounding the COVID-19 pandemic,~~contribution provided by our higher margin technology, e-commerce, and proprietary products and solutions. SmartPak and Covetrus-branded products and


Covetrus, Inc. 2021 Q1 Form 10-Q			19

Table of Contents

proprietary brands like Kruuse, Vi, and Calibra are included within our supply chain services major product category. Our prescription management ~~took certain temporary cost containment measures~~platform and compounding services are included within our prescription management major product category. To support these strategic initiatives, our corporate infrastructure spending will likely further increase to ~~help better align~~scale our ~~cost structure near-term, including executive, board,~~internal environment to support our continued acquisitive and ~~other senior-level employee compensation reductions, employee furloughs~~organic growth in ~~certain European countries, certain shift eliminations, a temporary hiring freeze, and discretionary spending deferrals. However,~~the animal-health market. We also expect to invest in internal initiatives to develop technology to be used across our ~~end-market across most geographies began~~business to ~~improve exiting April and demand further recovered in May and June~~drive greater efficiency as ~~deferred visits to veterinary practices recovered and demand trends normalized to pre-COVID-19 levels in some~~well as coordination of our ~~markets.~~global employee base.

~~Additionally, demand for our prescription management~~Terms with Key Suppliers, Customers, and ~~online pharmacy services increased~~Partners

Each year, suppliers in the ~~second~~veterinary channel engage in negotiations with us regarding pricing terms, including performance rebates and other growth incentives. Our supply chain services are dependent upon third-party suppliers, and the results of these negotiations, including whether the contractual relationship remains in place, can have a material impact on the financial performance of our business.

Effective January 1, 2021, we no longer are partnered with Merck & Co., in the U.K., which contributed to a decrease in our U.K. Net sales in the current quarter, and which we expect will also result in decreases for the remainder of this fiscal year. We also are no longer partnered with one of our customers in the U.K., which further decreased our U.K. Net sales, which we expect to continue throughout 2021. We are pursuing options to mitigate the effects of the supplier and customer loss in the U.K., and we do not expect the profitability impact to be significant. Our U.K. net sales as a ~~result~~percentage of ~~a shift~~our consolidated net sales decreased from 14% in ~~demand~~the first quarter of 2020 to ~~our online channel as a result~~9% in the first quarter of the pandemic, which could be temporary. These services address the need veterinarians have for continuity with pet owners and their ability to provide unique home delivery services that ties into their technological capabilities. The upward trend in telehealth technology began after the U.S. Food and Drug Administration relaxed its governance on telemedicine to allow more flexible veterinary examinations during the COVID-19 pandemic. To help veterinarians respond and deliver continued care during the COVID-19 pandemic, we also created resources for veterinary practices, including launching a series of webinars featuring practice managers and owners discussing strategies and real-world tactics.2021.

The ~~animal-health industry and veterinary-care sector have proven~~transition of our supply chain operations in Germany to ~~be more resilient than originally anticipated. Although the COVID-19 pandemic~~a third-party in late 2020 has ~~caused limited~~resulted in disruption to our ~~financial results as~~supply chain, including a reduction in customer sales volumes. We are making progress on stabilizing our customer base and improving service levels in this market. However, we ~~observed demand increases during~~are likely to experience lower sales volume for the near term. Our German operations represent 1% of our Net sales in the first half of 2020, the pandemic has been highly disruptive to established business practices and the buying patterns of our customers, both of which are currently fluid as the COVID-19 pandemic's effect on our macroeconomic environment is unpredictable. For example, our travel and entertainment expenses were significantly reduced in the second quarter of 2020 due to travel restrictions, which while disruptive, was beneficial in managing our operating expense. We expect that travel and entertainment expenses will return to previous levels when the COVID-19 pandemic eventually subsides. We believe that the actions we have taken will help us manage through the COVID-19 pandemic, however, our results in future quarters depend on the efficacy of containment procedures, the consequences of re-opening plans implemented globally, the lift on travel restrictions, and the subsequent impact on economic activity.

~~We began to ease some of the above-mentioned cash and liquidity conservation measures as the impact of the COVID-19 pandemic on our results of operations, to date, has been less than anticipated.~~For example, in July, we returned to pre-COVID-19 compensation levels and, in August, we expect to reinstate our 401(k)-employer match. Hiring for our business was strictly limited, especially in response to the COVID-19 pandemic; however, we are relaxing the restrictions we instituted as part of our temporary hiring freeze. At the same time, we continue to closely monitor global developments unfolding during the pandemic and may reinstate any measures that we reverse, or we may take additional actions to ensure we have enough liquidity for our business operations. In the absence of cost containment measures to manage our business in this dynamic COVID-19 environment, our selling, general and administrative expenses would likely increase throughout the remainder of 2020 as we continue our transformation.

To protect the health and safety of our employees, we implemented workplace regulations and recommended guidelines from government and public health authorities related to COVID-19. This includes frequent washing of hands, daily disinfecting of workspaces, and limiting non-essential travel. For employees who recently traveled to affected areas, a two-week quarantine is required prior to returning to work. In our pharmacies, it has been our standard practice to strictly comply with United States Pharmacopeia regulations on the use and application of personal protective equipment by all staff. In March 2020, we transitioned a large portion of our teams to working remotely and implemented staggered schedules in our distribution facilities. We created a COVID-19 information portal on our Covetrus intranet that provides best practices for working at home and staying connected, communications from our leadership, internal contacts for any COVID-19 questions, and helpful external reference links.

We assembled three cross-functional task forces that are actively planning return-to-work guidelines. These task forces represent North America, Europe, and APAC & Emerging Markets, and their goal is to develop a comprehensive plan to establish best practices for our essential facilities such as distribution centers and pharmacies and establish protocols for field-based employees to return to customer sites and for us to re-open Covetrus offices to safely accommodate more office-based employees.2021.

Our ~~re-open plan~~supplier relationships are currently concentrated because five suppliers accounted for approximately 50% of our purchases for the three months ended March 31, 2021 and for the year ended December 31, 2020. If we were to lose one of these five major manufacturing relationships, our global financial performance could be materially affected. As these contracts are largely annual and separated between supply chain and prescription management, our ability to exercise influence over the terms is ~~organized~~currently limited and negatively impacting our gross profit margin. We expect our future success necessitates achieving better terms and stronger relationships with our manufacturers and suppliers as we work with these partners on global initiatives. However, if a competitor is able to ~~address four main areas:~~

obtain better terms with suppliers in the veterinary channel or obtain exclusivity on products we typically sell to our Customers within the global animal-health market, our business could be impacted beyond the short term. We expect to also utilize our strategic growth initiatives to influence Customer and Animal-Owner brand loyalty, based on product launches on our prescription management platform, including launches of our own higher-margin proprietary products.

•

Acquisition-driven Amortization

~~Health & Safety - work schedules~~

As we pursue a growth strategy through acquisitions, we are likely to acquire intangible assets, such as customer relationships, trademarks, patents, product development (including formulas), and ~~rotations,~~non-compete agreements. Our intangibles are predominately comprised of intangibles acquired through our acquisition of Vets First Choice. These acquired intangibles have useful lives of 5 years for trademarks and trade names, 11 years for product formulas, 11 years for customer relationships, and 5 years for developed technologies.

The amortization of these intangibles has a long-term effect on our expense recognition. Product formulas are amortized to Cost of sales as these formulas are directly tied to the production of compounded products as alternatives to back-ordered solutions, patient-specific customized medications, and in-clinic use ~~of personal protective equipment, and protocols~~medications. Amortization expense for ~~employee health screening, sick notifications, on-site visitors, and more~~our other intangible assets not directly related to sales-generating activities, is included in SG&A.


	Three Months Ended March 31,
Location		2021		2020
Cost of sales		$	1	$	1
Selling, general and administrative		34		33
Total amortization expense		$	35	$	34

•~~Operations - establish best practices and guidance for employee workspace reconfiguration required to support social distancing, cleaning protocols, training, and compliance management~~

•~~Commercial - enable and support field-based employees in making customer visits and establish safety guidelines and strategies for our field sales teams~~


Covetrus, Inc. 2021 Q1 Form 10-Q			20

Table of Contents

•~~Communications - communicate updates of employee-related policies and provide materials, onsite signage, and employee training on updated protocols and policies~~

We will continue to actively monitor how COVID-19 is impacting us and may take further actions to alter our business operations in the best interests of our employees, customers, partners, suppliers, and stakeholders, or as required by federal, state, or local authorities.

~~Strategic Development~~

In 2020, we identified four priorities for our organization to drive forward our long-term strategic objectives: (i) creating a high-performing, customer-centric culture, (ii) maximizing effectiveness and efficiency, (iii) driving proprietary products and solutions, and (iv) expanding capabilities and developing sourcing excellence.

~~In the first half of 2020, we made progress on these objectives:~~

•~~We onboarded several leaders with experience in driving growth and transformation who represent an important facet of investing in our corporate culture and growing our talent globally.~~

•~~We instituted broad-based cost containment measures and spending discipline to provide flexibility within our organization as we adapt to the changing COVID-19 economic environment.~~

•We experienced strong utilization of our prescription management platform as we were well placed in the industry to provide dynamic solutions to our customers, so they could capitalize on the growth in e-commerce amidst the COVID-19 pandemic.

•~~We centralized our direct and indirect sourcing initiatives to coordinate purchasing activity and leverage our global scale.~~

While the global pandemic may have a continued impact on our business and could create new obstacles tied to achieving certain of our strategic objectives, our focus on building a shared culture of success, driving efficiencies throughout the organization, and executing against the core drivers of our business will remain.

Seasonality

Our quarterly sales and operating results have varied from ~~period-to-period~~period to period in the past and will likely continue to do so in the future. In the companion-animal market, sales of parasite protection products have historically tended to be stronger during the spring and summer months, primarily due to an increase in vector-borne diseases during that time, which correlates with our second and third quarters given that most of our business is in the northern hemisphere. Buying patterns can also be affected by manufacturers’ and distributors’ marketing programs or price increase announcements, which can cause ~~our customers~~veterinarians to purchase animal-health products earlier than when those products are needed. This kind of early purchasing may reduce our sales in the quarters these purchases would have otherwise been made. The sales of animal products can also vary due to changes in the price of commodities used in manufacturing the products and weather patterns, which may also affect period-over-period financial results. We expect our historical seasonality trends to continue in the foreseeable future.

Definition of Non-GAAP Adjusted Earnings Before Interest, Taxes, Depreciation, and Amortization

Adjusted EBITDA is a non-GAAP financial measure used to (i) aid management and investors with year-over-year comparability, (ii) determine management performance under our compensation plans, (iii) plan and forecast, (iv) communicate our financial performance to our Board of Directors, shareholders, and investment analysts, and (v) understand our operating performance without regard to items we do not consider a component of our core ongoing operating performance. Adjusted EBITDA has certain limitations in that it does not consider the impact of certain expenses to our consolidated statements of operations. Adjusted EBITDA excludes share-based compensation, strategic consulting, transaction costs, formation of Covetrus expenses, separation programs and executive severance, carve-out operating expenses, certain IT infrastructure expenses necessary to establish ourselves as a newly public company, goodwill impairment charges, capital structure-related fees, operating lease right-of-use asset impairments, the proportionate share of the adjustments to EBITDA of consolidated and non-consolidated affiliates where Covetrus ownership is less than 100%, managed exits from businesses we are exiting or closing, and other income and expense items, net. Currently, we do not allocate expenses managed at the corporate level, such as corporate wages and related benefits, corporate occupancy costs, professional services utilized at the corporate level, and non-recurring expenses to our operating segments. Other companies may not define or calculate Adjusted EBITDA in the same way. We provide Adjusted EBITDA by segment as a supplemental measure to GAAP as well as on a consolidated, non-GAAP basis. Non-GAAP Adjusted EBITDA on a total segment basis is reconciled in Note 2 - Segment Data as required by ASC 280.

Results of Operations


	Three Months Ended
(In millions)		March 31, 2021		March 31, 2020		$ Increase (Decrease)		% Increase (Decrease)
Net sales		$	1,102	$	1,065	$	37	3	%
Cost of sales		892		863		29		3
Gross profit		210		202		8		4
Operating expenses:
Selling, general and administrative		213		222		(9)		(4)


Operating income (loss)		$	(3)	$	(20)	$	(17)	(85)	%

Interest expense, net		$	(9)	$	(14)	$	(5)	(36)	%
Other, net		$	—	$	(1)	$	1	(100)	%

Net income (loss)		$	(16)	$	(33)	$	(17)	(52)	%
Net income (loss) attributable to Covetrus		$	(16)	$	(33)	$	(17)	(52)	%

~~Table of Contents~~

~~Results of Operations~~

Three Months Ended Six Months Ended
(In millions) June 30, 2020 June 30, 2019 $ Increase (Decrease) % Increase (Decrease) June 30,
2020 June 30,
2019 $ Increase (Decrease) % Increase (Decrease)
Net sales $ 1,026 $ 1,009 $ 17 1.7 % $ 2,091 $ 1,950 $ 141 7.2 %
Cost of sales 834 816 18 2.2 1,696 1,580 116 7.3
Gross profit 192 193 (1) (0.5) 395 370 25 6.8
Operating expenses:
Selling, general and administrative 196 198 (2) (1.0) 419 384 35 9.1
Operating loss $ (4) $ (5) $ (1) (20.0) % $ (24) $ (14) $ 10 71.4 %
Interest expense, net $ (13) $ (13) $ — — % $ (27) $ (23) $ 4 17.4 %
Other, net^(a)
$ 76 $ 13 $ 63 484.6 % $ 75 $ 15 $ 60 400.0 %
Net income (loss) $ 54 $ (10) $ 64 640.0 % $ 21 $ (23) $ 44 191.3 %
Net income (loss) attributable to Covetrus $ 54 $ (10) $ 64 640.0 % $ 20 $ (23) $ 43 187.0 %
(a) Includes a $73 million gain on the divestiture of scil and a $1 million gain on the deconsolidation of SAHS. See Note 3 - Divestiture and Equity Method Investment.

The year-over-year increase in Net sales for the three months ended June 30, 2020 compared to the three months ended June 30, 2019 was primarily due to strong prescription management growth, improved performance across certain of our markets supported by the end-market recovery, and acquisitions, partially offset by COVID-19 stocking activity that occurred in the first quarter of 2020, pulling demand out of the second quarter, divestitures, and unfavorable foreign exchange.

The year-over-year increase in Net sales for the six months ended June 30, 2020 compared to the six months ended June 30, 2019 was primarily due to strong prescription management growth, improved performance across certain of our markets, and acquisitions, partially offset by unfavorable foreign exchange and divestitures.

The year-over-year improvement in Operating loss for the three months ended June 30, 2020 compared to the three months ended June 30, 2019 was largely due to strong prescription management growth, and cost containment measures initiated due to the COVID-19 pandemic, largely offset by the effect of divestitures and increased expenses to drive our transformation as an independent, global public company.

The year-over-year increase in Operating loss for the six months ended June 30, 2020 compared to the six months ended June 30, 2019 was due to the increase from acquisitions (primarily Vets First Choice) and increased expenses to drive our transformation as an independent, global public company, partially offset by strong prescription management growth and cost containment measures initiated due to the COVID-19 pandemic.

Net income during the three and six months ended June 30, 2020 as compared to the three and six months ended June 30, 2019 was positively impacted by the gain on the divestiture of scil as well as the items above.


Covetrus, Inc. 2021 Q1 Form 10-Q			21

Table of Contents

Year-Over-Year Period Comparisons

Net Sales


		Three Months Ended														Six Months Ended									Three Months Ended
(In millions)	(In millions)	June 30, 2020		June 30, 2019		$ Change		% Change		June 30, 2020		June 30, 2019		$ Change		% Change		(In millions)	March 31, 2021		March 31, 2020		$ Change		% Change
North America	North America	$	602	$	552	$	50	9.1	%	$	1,152	$	1,049	$	103	9.8	%	North America	$	635	$	550	$	85	15	%
Europe	Europe	342		370		(28)		(7.6)		764		731		33		4.5		Europe	361		422		(61)		(14)
APAC & Emerging Markets	APAC & Emerging Markets	85		90		(5)		(5.6)		180		176		4		2.3		APAC & Emerging Markets	112		95		17		18
Eliminations	Eliminations	(3)		(3)		—		—		(5)		(6)		1		(16.7)		Eliminations	(6)		(2)		(4)		200
Total Net sales	Total Net sales	$	1,026	$	1,009	$	17	1.7	%	$	2,091	$	1,950	$	141	7.2	%	Total Net sales	$	1,102	$	1,065	$	37	3	%

Net sales for the three months ended ~~June 30, 2020~~March 31, 2021 increased compared to the three months ended ~~June 30, 2019~~March 31, 2020 primarily due to ~~a $43 million increase from strong~~favorable foreign exchange, prescription management growth, ~~improved performance across certain~~and supply chain organic growth. Consolidated supply chain organic growth was heavily affected by the decrease in Europe, largely driven by the loss of Merck & Co. as a supply partner as well as a loss of a customer, both in the U.K., and disruption in our ~~markets as the COVID-19 impact eased, and the contribution of $17 million~~supply chain operations resulting from our transition to a third- party logistics provider in Germany. The overall increase in net sales ~~from acquisitions,~~was partially offset by ~~COVID-19 stocking activity~~net sales that are no longer being contributed following our disposition of scil, the deconsolidation of a subsidiary in Spain, and the managed exit of our French distribution business, all of which occurred inafter the first quarter of ~~2020, pulling demand out of the second quarter, $27 million in net sales from divestitures, and $22 million in unfavorable foreign exchange.~~2020. The drivers by segment are detailed below:

•North America increased primarily due to ~~strong~~$59 million in net supply chain organic growth inand a $28 million increase from prescription management ~~which contributed a $43~~growth, partially offset by $3 million ~~increase~~ in net ~~sales. Supply chain net~~ sales ~~(net~~related to our divestiture of ~~eliminations) increased 2% as strong net sales~~scil in ~~June offset~~ the ~~decline in April and May as a result~~second quarter of ~~fluctuating customer and animal owner demand due to COVID-19.~~2020.

•Europe decreased primarily due to a ~~COVID-19 related slowdown~~$46 million decrease in net supply chain sales and a $39 million decrease from divestitures that occurred in 2020 as the ~~large-animal market, particularly in the United Kingdom, disposition of scil and the deconsolidation of a subsidiary in Spain that decreased~~divested businesses contributed net sales ~~by $24 million, and unfavorable foreign currency exchange~~for the entirety of ~~$12 million.~~the first quarter of 2020. These decreases were partially offset by a favorable foreign exchange impact of $27 million, positive organic growth in ~~certain~~several markets including the Netherlands, Ireland, and Belgium, and strong performance in proprietary brands of ~~our markets in the region,~~Kruuse and ~~the contribution of $16 million from our acquisitions in France (July 2019) and Romania (May 2019) being present for the full period in 2020.~~

•~~APAC & Emerging Markets decreased primarily due to unfavorable foreign exchange of $10 million and COVID-19 stocking activity that occurred in the first quarterof 2020, partially offset by strong underlying organic growth in the region.~~

Net sales for the six months ended June 30, 2020 increased compared to the six months ended June 30, 2019 primarily due to a $71 million increase from strong prescription management growth, improved performance across certain of our markets, and contribution of $67 million in net sales from acquisitions, including $24 million from the acquisition of Vets First Choice being present for a complete half year of sales this year versus only 4.5 months in 2019 (February 8 - June 30, 2019), partially offset by $41 million due to unfavorable foreign exchange and $27 million effect on net sales from divestitures. The drivers by segment are detailed below:

•North America increased primarily due to an increased contribution of $71 million from strong prescription management growth and $24 million from the acquisition of Vets First Choice being present for a complete half year of sales this year versus only 4.5 months in 2019 (February 8 - June 30, 2019). The increase in supply chain net sales was partially offset by the loss of a customer in the first quarter of 2019.

•Europe increased primarily due to $41 million from our acquisitions in France and Romania being present for the full period in 2020 and organic growth in most of our markets in the region, partially offset by $24 million from the disposition of scil and the deconsolidation of a subsidiary in Spain, and unfavorable foreign currency exchange of $23 million.Vi.

•APAC & Emerging Markets increased primarily due to favorable foreign exchange of $10 million and strong underlying supply chain organic growth in the ~~contribution of $21~~region contributing to $6 million in net sales ~~from organic~~ growth. ~~These increases were partially offset by unfavorable foreign exchange of $19 million.~~

~~Table of Contents~~

Gross Profit and Gross Profit Margin


		Three Months Ended																							Three Months Ended
(In millions)	(In millions)	June 30, 2020		Gross Margin %		June 30, 2019		Gross Margin %		$ Change		Gross Profit % Change		(In millions)	March 31, 2021		Gross Margin %		March 31, 2020		Gross Margin %		$ Change		Gross Profit % Change
North America	North America	$	127	21.1	%	$	119	21.6	%	$	8	6.7	%	North America	$	131	20.6	%	$	119	21.6	%	$	12	10	%
Europe	Europe	48		14.0		57		15.4		(9)		(15.8)		Europe	55		15.2		64		15.2		(9)		(14)
APAC & Emerging Markets	APAC & Emerging Markets	17		20.0		17		18.9		—		—		APAC & Emerging Markets	24		21.4		19		20.0		5		26
Total Gross profit	Total Gross profit	$	192	18.7	%	$	193	19.1	%	$	(1)	(0.5)	%	Total Gross profit	$	210	19.1	%	$	202	19.0	%	$	8	4	%

During the three months ended June 30, 2020, the decrease in gross profit was largely driven by $8 million from divestitures, unfavorable foreign exchange of $4 million, and a COVID-19 related slowdown in the large-animal market in Europe, particularly in the United Kingdom. These decreases were partially offset by a $13 million increase related to strong prescription management growth and $2 million from acquisitions. The drivers of the decrease in our gross profit are further detailed below by segment:

•~~North America increased primarily due to strong prescription management growth which contributed $13 million, partially offset by lower agency sales and rebate timing in our supply chain business.~~

•Europe decreased primarily due to the disposition of scil and the deconsolidation of a subsidiary in Spain, which decreased gross profit by $7 million, COVID-19 stocking activity that occurred in the first quarterof 2020, pulling demand out of the second quarter, and unfavorable foreign exchange of $2 million. These decreases were partially offset by the contribution of $2 million from our acquisitions in France and Romania being present for the full period in 2020.

•~~APAC & Emerging Markets remained constant, unfavorable foreign exchange effects of $2 million were offset by improved performance in certain markets in the region.~~

Six Months Ended
(In millions) June 30, 2020 Gross Margin % June 30, 2019 Gross Margin % $ Change Gross Profit % Change
North America $ 247 21.4 % $ 224 21.4 % $ 23 10.3 %
Europe 112 14.7 112 15.3 — —
APAC & Emerging Markets 36 20.0 34 19.3 2 5.9
Total Gross profit $ 395 18.9 % $ 370 19.0 % $ 25 6.8 %

~~During the six months ended June 30, 2020,~~March 31, 2021, the increase in gross profit compared to the ~~six~~three months ended ~~June 30, 2019~~March 31, 2020 was largely driven by ~~a $20 million increase from strong~~favorable foreign exchange, prescription management growth, ~~$15 million~~supply chain organic growth, and an increase from ~~acquisitions being present for~~our acquisition of VSG in the ~~full~~fourth quarter of 2020, which is contributing gross profit in 2021 but has no comparable basis in the same period of 2020. Consolidated supply chain gross profit was heavily affected by the decrease in ~~2020 versus~~Europe, largely due to disruption in our supply chain operations resulting from our transition to a ~~partial period~~third-party logistics provider in ~~2019,~~Germany and the loss of Merck & Co. as a supply partner as well as ~~improved performance across certain distribution markets.~~a loss of a customer, both in the U.K. These increases in gross profit were partially offset by ~~$8 million from~~ the disposition of scil, ~~and~~ the deconsolidation of a subsidiary in Spain, and ~~unfavorable foreign exchange~~the managed exit of ~~$7 million.~~our French distribution business, as the divested businesses contributed gross profit for the entirety of the first quarter of 2020. The drivers of the increase in our gross profit are further detailed below by segment:

•North America increased primarily due to the ~~acquisition and~~ growth of our prescription management ~~business.~~business of $6 million, $4 million from supply chain organic growth, and $2 million from our acquisition of VSG in the fourth quarter of 2020, which is contributing gross profit in 2021 but has no comparable basis in same period of 2020.


Covetrus, Inc. 2021 Q1 Form 10-Q			22

Table of Contents

•Europe ~~was flat, with~~decreased primarily due to $9 million from divestitures that occurred in 2020 as the $7divested businesses contributed gross profit for the entirety of the first quarter of 2020 and a $4 million decrease in supply chain gross profit, partially offset by favorable foreign exchange of $4 million. Our proprietary brands are also contributing higher gross profit which is lessening the impact from the disposition of scil and the deconsolidation of a subsidiary in Spain, and unfavorable foreign exchange effects, offset by acquisitions being present for the full period in 2020 versus a partial period in 2019 and improved performance across certain distribution markets.disruptions noted above.

•APAC & Emerging Markets increased due to the contribution of $6$3 million from organic growth, ~~partially offset by unfavorable~~primarily related to supply chain, and favorable foreign exchange of $4$2 million.

~~Table of Contents~~

SG&A

~~Selling, General and Administrative (~~“~~SG&A~~”)


		Three Months Ended														Six Months Ended									Three Months Ended
(In millions)	(In millions)	June 30, 2020		June 30, 2019		$ Change		% Change		June 30, 2020		June 30, 2019		$ Change		% Change		(In millions)	March 31, 2021		March 31, 2020		$ Change		% Change
North America	North America	$	114	$	127	$	(13)	(10.2)	%	$	235	$	225	$	10	4.4	%	North America	$	124	$	121	$	3	2	%
Europe	Europe	39		45		(6)		(13.3)		92		89		3		3.4		Europe	42		53		(11)		(21)
APAC & Emerging Markets	APAC & Emerging Markets	13		15		(2)		(13.3)		27		29		(2)		(6.9)		APAC & Emerging Markets	14		13		1		8
Corporate	Corporate	30		11		19		172.7		65		41		24		58.5		Corporate	33		35		(2)		(6)
Total SG&A	Total SG&A	$	196	$	198	$	(2)	(1.0)	%	$	419	$	384	$	35	9.1	%	Total SG&A	$	213��	$	222	$	(9)	(4)	%

SG&A expenses for the three months ended ~~June 30, 2020~~March 31, 2021 decreased compared to ~~the same~~prior year period ~~in 2019,~~ primarily due to ~~the cost containment measures initiated~~a decrease in ~~response to the COVID-19 pandemic, $7 million from the disposition of scil and the deconsolidation of a subsidiary in Spain, offset by an increase of $2 million in SG&A from acquisitions and increased~~ expenses ~~to drive~~that are no longer being incurred following our ~~transformation as an independent, global public company. The drivers by segment and at Corporate are detailed below:~~

•North America decreased primarily due to lower share-based compensation expense and COVID-19 related cost containment measures, partially offset by increased expenses associated with strong prescription management growth.

•Europe decreased primarily due to $6 million from the disposition of scil and the deconsolidation of a subsidiary in Spain, COVID-19 related cost containment measures, as well as a favorable foreign exchange impact of $1 million, partially offset by the impact from acquisitions in France and Romania of $2 million.

•~~APAC & Emerging Markets decreased due to favorable foreign exchange of $2 million.~~

•Corporate increased primarily due to increased share-based compensation expense, strategic consulting fees of $5 million, and increased costs related to various corporate functions as we continue to establish ourselves as an independent, global public company.

SG&A expenses for the six months ended June 30, 2020 increased compared to the same period in 2019, primarily due to the increase of $25 million in SG&A from acquisitions (primarily Vets First Choice) and increased expenses to drive our transformation as an independent, global public company, partially offset by decreases due to the disposition of scil, the deconsolidation of a subsidiary in Spain, ~~COVID-19 cost containment measures,~~ and ~~favorable~~the managed exit of our French distribution business, a decrease in transaction costs largely driven by the absence of divestitures in 2021, decreased travel and advertising expense, a decrease in expense related to the formation of Covetrus, and decreased strategic consulting fees. These decreases were partially offset by increased costs to support the growth in our prescription management business, an unfavorable foreign exchange effect, increased costs incurred as we continue to invest in innovation and corporate infrastructure to enable our growth, and increased expense from VSG following our acquisition in the fourth quarter of ~~$5 million.~~2020. The drivers by segment and at Corporate are detailed below:

•North America increased primarily due to ~~the~~an increase of $3 million from our acquisition of ~~Vets First Choice which contributed $19~~VSG and $3 million ~~from a complete half-year~~ of ~~SG&A expenses for~~increased costs to support the ~~six months ended June 30, 2020 versus a 4.5 months last year,~~growth in our prescription management business, partially offset by ~~lower share-based compensation expenses.~~a decrease in travel and advertising expense of $3 million. Acquisition-related intangible amortization was 25% of North America SG&A in 2021 and 24% in 2020.

•Europe ~~increased~~decreased primarily due to ~~the impact of $6~~$9 million from ~~acquisitions~~expenses that are no longer being incurred following divestitures that occurred in ~~France and Romania being present for the full period in~~ 2020, reduced transaction costs of $2 million ~~as well as increased IT~~largely from the absence of divestitures in 2021, a $1 million decrease in travel and ~~facility costs associated with~~advertising expense, and $1 million in decreased expenses related to the formation of ~~Covetrus as we exit our Transition Service Agreements.~~Covetrus. These ~~increases~~decreases were partially offset by $6an increase of $3 million ~~from the disposition of scil and the deconsolidation of a subsidiary in Spain.~~due to unfavorable foreign exchange.

•APAC & Emerging Markets ~~decreased~~increased primarily due to ~~favorable~~unfavorable foreign ~~exchange of $3 million.~~exchange.

•Corporate ~~grew~~decreased primarily due to a $4 million decrease in transaction costs, a $3 million decrease in expenses related to the formation of Covetrus, and decreased strategic consulting fees of $2 million. These decreases were partially offset by $3 million of increased costs ~~of $9 million related to various corporate functions~~incurred as we continue to ~~establish ourselves as an independent, global public company, strategic consulting fees of $9~~invest in innovation and our corporate infrastructure to enable our growth and $1 million ~~and transaction costs of $4 million.~~

~~See section~~ ~~Impact of COVID-19 on our Business~~ ~~above for more information on our COVID-19 cost containment measures.~~

~~Table of Contents~~

~~Other, net~~

~~Other, net during the three and six months ended June 30, 2020 as compared~~from increased short-term incentive bonus attributable to ~~the three and six months ended June 30, 2019 was positively impacted by the gain on the divestiture of scil, as well as a gain on our deconsolidation of our subsidiary, SAHS, in Spain.~~Corporate.

Income ~~taxes~~Taxes

Income tax expense for the three months ended ~~June 30, 2020~~March 31, 2021 was $6$4 million on a loss before ~~income~~ taxes and equity in earnings inof affiliates of ~~$59 million for a consolidated effective tax rate of 10.6%.~~$12 million. The difference between our ~~effective~~ tax ~~rate~~expense and the tax expense using the statutory tax rates for the jurisdictions in which we operate, for ~~the three months ended June 30, 2020,~~this period, primarily related to valuation allowances due to uncertainty regarding the realization of future tax benefits from certain U.S. deferred tax ~~assets and the sale of scil business units.~~assets.

~~Income~~The income tax ~~expense~~benefit for the ~~six~~three months ended ~~June 30,~~March 31, 2020 was $4$2 million on ~~income~~a loss before taxes and equity in earnings of affiliates of ~~$24 million for a consolidated effective tax rate of 17.7%.~~$35 million. The difference between our ~~consolidated effective~~ tax ~~rate~~expense and the ~~federal~~tax expense using the statutory tax rates for the jurisdictions in which we operate, for ~~the six months ended June 30, 2020,~~this period, primarily related to ~~non-deductible share-based compensation expense, the sale of scil business units,~~ valuation allowances due to uncertainty regarding the realization of future tax benefits from certain U.S. deferred tax assets and ~~the federal tax impact~~non-deductible expenses associated with share-based compensation.


Covetrus, Inc. 2021 Q1 Form 10-Q			23

Table of ~~international operations included as GILTI.~~

Contents

Income tax expense for the three months ended June 30, 2019 was $5 million on a loss before income taxes and equity earnings in affiliates of $5 million for a consolidated effective tax rate of (94.8)%. The difference between our effective tax rate and the statutory tax rates for the jurisdictions in which we operate for the three months ended June 30, 2019, primarily related to the change from using the actual effective tax rate methodology for the three months ended March 31, 2019 to an annualized effective tax rate methodology for the three and six months ended June 30, 2019.

Income tax expense for the six months ended June 30, 2019 was $1 million on a loss before taxes and equity in earnings of affiliates of $22 million for a consolidated effective tax rate of (2.4)% The difference between our effective tax rate and the federal statutory tax rates for the jurisdictions in which we operate for the six months ended June 30, 2019, primarily related to the federal tax impact of international operations included as GILTI and non-deductible share-based compensation expense.

Adjusted EBITDA


		Three Months Ended														Six Months Ended									Three Months Ended
(In millions)	(In millions)	June 30, 2020		June 30, 2019		$ Change		% Change		June 30, 2020		June 30, 2019		$ Change		% Change		(In millions)	March 31, 2021		March 31, 2020		$ Change		% Change
North America	North America	$	55	$	43	$	12	27.9	%	$	96	$	78	$	18	23.1	%	North America	$	52	$	41	$	11	27	%
Europe	Europe	16		19		(3)		(15.8)		34		35		(1)		(2.9)		Europe	21		18		3		17
APAC & Emerging Markets	APAC & Emerging Markets	5		4		1		25.0		12		8		4		50.0		APAC & Emerging Markets	10		7		3		43
Corporate	Corporate	(13)		(13)		—		NA		(31)		(16)		(15)		NA		Corporate	(26)		(18)		(8)		NA
Total Adjusted EBITDA	Total Adjusted EBITDA	$	63	$	53	$	10	18.9	%	$	111	$	105	$	6	5.7	%	Total Adjusted EBITDA	$	57	$	48	$	9	19	%

Total non-GAAP Adjusted EBITDA for the three months ended ~~June 30, 2020~~March 31, 2021 increased 19% compared to the same period in ~~2019,~~2020, largely due to ~~strong prescription management growth~~improved performance across certain of our markets, including increased contribution from higher margin businesses, and ~~cost containment measures,~~a favorable foreign exchange impact, partially offset by increasing costs incurred as we ~~transform into an independent, global public company.~~continue to invest in innovation and our corporate infrastructure to enable our growth. The changes by segment and at Corporate are detailed below:

•North America increased primarily due to ~~strong~~$6 million in supply chain services from organic growth, $2 million growth in our prescription management ~~growth~~business, and ~~cost containment measures.~~the contribution of adjusted EBITDA from VSG's operations in 2021.

•Europe ~~decreased primarily due to~~experienced a $5 million increase in contribution from our higher margin proprietary brands that was offset by $5 million decreases comprised of the ~~disposition~~loss of ~~scil~~Merck & Co. as a supply partner and a loss of a customer, both in the U.K., and the ~~deconsolidation~~disruption from our transition to a third-party logistics provider in Germany. Following these offsetting effects, Europe increased $2 million from favorable foreign exchange as well as the continuing impact of ~~a subsidiary in Spain, partially offset by acquisitions and~~ cost containment ~~measures.~~

•~~APAC & Emerging Markets increased primarily due organic growth and cost containment measures, partially offset by unfavorable foreign exchange.~~

•~~Corporate adjusted EBITDA remained constant as our cost containment measures were offset by increased costs as we continue to establish ourselves as an independent, global public company.~~

~~Table of Contents~~

Total non-GAAP Adjusted EBITDA for the six months ended June 30, 2020 increased compared to the same period in 2019, largely due to strong prescription management growth, partially offset by increasing costs incurred as we transform into an independent, global, public company. The changes by segment and at Corporate are detailed below:

•~~North America increased primarily due to the acquisition and strong growth of our prescription management business.~~

•Europe decreased primarily due to the disposition of scil and the deconsolidation of a subsidiary in Spain and unfavorable foreign exchange, partially offset by acquisitions and cost containment measures.actions.

•APAC & Emerging Markets increased primarily due to $2 million in organic growth ~~partially offset by unfavorable foreign exchange.~~mainly related to supply chain.

•Corporate contributed ~~a $15~~an $8 million decrease ~~in adjusted EBITDA~~ primarily due to ~~SG&A~~$3 million in increased expenses incurred as we continue to ~~establish ourselves as an independent, global public company.~~invest in innovation and our corporate infrastructure to enable our growth, $2 million from unfavorable foreign exchange transaction loss related to intercompany notes, and $1 million from increased short-term incentive bonus attributable to Corporate.

Liquidity and Capital Resources

~~Impact of COVID-19 on Liquidity and Capital Resources~~Overview

~~During~~Our primary sources of liquidity are cash and cash equivalents, cash flows from the ~~short period~~operations of ~~time that COVID-19 took to become a global pandemic, it had a rapid, negative impact on global~~our business, and available borrowing capacity under our Credit Facilities. Our principal uses of cash include working capital-related items, capital ~~markets. Many equity prices tumbled~~expenditures, debt service, and the investment funds flowing into certain debt markets paused or became more expensive to borrowers, and the recovery of these capital markets has been mixed with still uncertain forecasts. In response, some governments offered deferred tax schemes, guarantees, and loan programs to individuals, small businesses, and larger companies as methods to boost liquidity, maintain workforces, to help soften the impact of COVID-19 on capital structures and financial results of businesses. We are not immune to the impact of COVID-19 and have taken and continue to take steps to improve our liquidity position as a result.strategic investments.

Credit Facilities

The Credit Facilities include a Term Loan Facility and a Revolving Credit Facility. There were no borrowings from the Revolving Credit Facility as of March 31, 2021 and December 31, 2020.

Short-Term

Our liquidity fluctuates during the year due to sales seasonality. Generally, our sales of parasite protection products in the companion-animal market peak during the spring and summer months, which are hemisphere dependent, as vector-borne diseases typically increase during these seasons. This seasonality also affects the timing and amount of our inventory purchases, and subsequently our accounts payable balances.

We also operate on a disciplined, global approach to inventory management, including replenishing stock as sales deplete inventory to lower holding levels, executing inventory buy-ins only when price discounts make economic sense with no outsized working capital effect, or when vendor rebate targets are within reasonable reach with incremental purchases and no meaningful impact on cash forecasts.

Planned investments included in our near-term strategic plan:


Covetrus, Inc. 2021 Q1 Form 10-Q			24

Table of Contents

•Pharmacy innovation and operational capacity in Arizona and Maine

•Enhancing the consumer experience through continuous improvements in e-Commerce, appointment management, and veterinarian to pet owner connectivity

•Cloud-based practice management software development and coordination with select existing service offerings

•Business-to-business ordering capabilities focused on our compounding services, distribution, and inventory management services

•Optimizing our distribution network in North America, including investments in the systems that support our network like our warehouse management system

•Implementing a regional-wide enterprise resource planning system in Europe to reduce complexity in our global enterprise resource planning landscape

•We continuously evaluate external growth opportunities that support our strategic objectives and may make acquisitions and investments earlier or later than we expect, including that some acquisitions and investments may not come to fruition. In ~~April~~connection with our creation of Distrivet in 2020, we ~~completed~~were contractually obligated to pay $12 million to the ~~sale~~former owners of ~~our scil animal-care business under challenging business conditions, which provided cash proceeds~~Distrivet S.A. on the one-year anniversary of approximately $104 million, which represents gross proceeds of $110 million, net of cash included in the sale. We used $45 million of these proceeds to prepay our remaining quarterly term loan principal amortization payments for 2020. On May 19, 2020, we sold our Series A Preferred Stock in a private placement transaction for $244 million in net proceeds to further enhance our liquidity position. A portion of the Series A Preferred Stock proceeds, coupled with cash flow generated from better than anticipated sales during COVID-19, was used to repay our revolver borrowings earlier than expected, with the remainder used to support general corporate purposes (see closing, or April 30, 2021

~~Note 12 - Redeemable Series A Convertible Preferred Stock).~~

Trends

Our operational plans to manage our liquidity continue to ~~include reducing~~involve seeking opportunities to reduce non-critical capital expenditures, sharpening our focus on collecting supplier rebates and amounts owed to us by customers, ~~and for supplier rebates,~~ managing opportunistic inventory purchases as we carefully monitor sales forecasts and timing of projected price increases, quickly reducing our other costs, ~~considering~~and maximizing our payment terms wherever possible. We also continue to monitor cash flow projections and will consider additional borrowings, if needed, based on availability under our ~~revolving credit facility~~Revolving Credit Facility from ~~time-to-time,~~time to time.

In December 2020, we fully prepaid the 2021 Term Loan Facility's amortization payments which reduced our outstanding balance and ~~maximizing our~~lowered the applicable monthly floating interest rates. The next quarterly principal amortization payment ~~terms wherever possible.~~of $15 million is due on March 31, 2022.

Our interest ~~expense was slightly higher during~~rate swap contracts, which effectively fix the ~~six months ended June 30, 2020 due to~~borrowing rates on a portion of our floating rate debt, mature on July 31, 2021. Based on the revolver borrowings that were outstanding at the beginning of the quarter. However, that increase was mitigated by fully paying the required $60 million 2020 amortization payments to reduce our term loan outstanding and lower monthlycurrent floating interest ~~rates applicable to~~rate environment, we anticipate that we will incur lower interest expense, at least for a period of time, following the term loan. The February 2020 amendment to our credit agreement modified the leverage-based grid that determines the applicable margin to be added to our borrowings, which applicable margin increases as credit agreement-defined leverage increases or decreases as credit agreement-defined leverage decreases. In addition, this amendment will permit us to maintain revolving credit facility borrowings near term, if needed, and help alleviate some potential COVID-19 impact to our earnings, while remaining compliant with our debt covenants as the step downmaturity of our ~~leverage covenant from 5.50x to 5.00x was delayed until June 30, 2021.~~ interest rate swap contracts.

We were in compliance with the covenants in our ~~credit agreement~~Credit Facilities as of ~~June 30, 2020.~~March 31, 2021. Based on our expected ~~credit agreement-defined~~Credit Facilities-defined leverage as of ~~the three months ended June 30, 2020,~~March 31, 2021, once the quarterly ~~credit agreement~~ compliance filing is made, the current applicable margin on our ~~credit agreement~~ borrowings outstanding will ~~decrease which will result in lower interest expense~~remain unchanged at least until the next compliance filing is made for the three months ~~ending September~~ended June 30, ~~2020.~~2021. Based on the revised schedule contained in the 2020 amendment to our Credit Facilities, we are required to remain compliant with a Credit Facilities-defined leverage covenant that is currently set at 5.50x, but will decrease by 0.5x as of June 30, 2021, then an additional 0.5x as of December 31, 2021, and finally to 3.75x as of June 30, 2022 through maturity of the Credit Facilities. The decrease in this particular financial covenant and our required compliance may influence our investment decisions.

The duration of the COVID-19 pandemic iscontinues to be unknown. Should the pandemic extend throughout ~~the rest of 2020~~2021 and beyond, or the severity of variant strains increase that reduces the effectiveness of vaccines and negatively impacts global economic conditions, then we may experience a negative impact on our liquidity position. Therefore, we continuously assess steps we can take to improve working capital and increase cash on our balance sheet, ~~research government-backed loan~~investigate government sponsored financing or tax holiday programs that may be available to us or to our customers, and closely monitor the capital markets for additional opportunities to improve our liquidity position.

Long-term

Our long-term liquidity is expected to be aligned with our strategic development, and the needs of our growing business in terms of investment to fund growth, as well as availability of financing. We currently anticipate the following long-term liquidity trends for our business:

Uses of liquidity:

•Investing in our expansion of global sales and marketing efforts

•Launching new products and services

•Pursuit of strategic, higher-margin acquisition and investment targets

•Increasing our pharmaceutical compounding operations capacity

•International development of presence, product, and service offerings


Covetrus, Inc. 2021 Q1 Form 10-Q			25

Table of Contents

~~Overview~~•Term Loan Facility amortization payments (beginning again in March 2022)

•Ongoing operating lease payments

•Capital investments in current and future facilities

•Pursuit and maintenance of appropriate regulatory clearances, approvals for existing products, and any new products that may be developed

Sources of liquidity:

•Operations-driven cash generation

•Borrowings on our Revolving Credit Facility

•Availability of financing through the capital markets

Our ~~primary sources~~Term Loan Facility and Revolving Credit Facility bear interest on a floating rate basis at our option, which are referenced to LIBOR. The banking syndicate associated with our Credit Facilities intends to cease using the 1-week and 2-month USD LIBOR at the end of ~~liquidity are cash and cash equivalents, cash flows from~~2021, with the ~~operations of~~other USD Tenors to cease June 30, 2023. Our Credit Facilities, with which we primarily elect to reference 1-month USD LIBOR for our ~~business, available borrowing capacity under our credit facility, and cash proceeds received from divestitures.~~ borrowings, will be amended to reflect the replacement basis rate accordingly, when identified.

Longer term, if we desire to access alternative sources of funding through the capital and credit markets, challenging global economic conditions, such as a long-lasting COVID-19 pandemic or economic downturn, could adversely impact our ability to do so. ~~Our principal uses of cash include working capital-related items, capital expenditures, debt service, and strategic investments.~~

Working capital requirements, which can be substantial and susceptible to fluctuations during the year due to seasonal demands, generally result from sales growth, inventory purchase patterns driven by sales activity and buy-in opportunities, our desired level of inventory, and payment terms for receivables and payables.

~~Under normal historical operating conditions, we would expect to incur additional disbursements in connection with the following:~~

•~~expansion of global sales and marketing efforts~~

•~~increase of our pharmaceutical operations capacity~~

•~~international development~~

•~~equity investment and business acquisitions that we may fund from time to time~~

•~~term loan facility amortization payments (prepaid for 2020, but beginning again in March 2021)~~

•~~capital investments in current and future facilities~~

•~~pursuit and maintenance of appropriate regulatory clearances, approvals for existing products, and any new products that may be developed~~

Depending on how our results from operations continue for the remainder of 2020, we may decide to pursue some of the opportunities noted above. Regardless, we anticipate that we will continue to incur significant interest expense related to debt service on the credit facility.

We regularly monitor and assess our ability to meet funding requirements. We expect to meet our foreseeable liquidity requirements through cash and cash equivalents, cash flow from operations, access to available funds by borrowing against our credit facility, and net cash proceeds received from divestitures of non-core business operations. Our decisions to use available liquidity will be based upon the duration of the COVID-19 pandemic and our continuing review of the funding needs for our business, optimizing the allocation of cash resources for investments, capital structure changes or business combinations, and the timing of cash flow generation.

Cash and Cash Equivalents

As of ~~June 30, 2020,~~March 31, 2021, we had Cash and cash equivalents of ~~$414~~$211 million. We consider all highly liquid short-term investments with an original maturity of three months or less to be cash equivalents. Due to the short-term maturity of such investments, the carrying amounts are a reasonable estimate of fair value.

Cash Flows

The following table summarizes our cash flows from operating, investing, and financing activities:


		Six Months Ended											Three Months Ended
(In millions)	(In millions)	June 30, 2020		June 30, 2019		$ Change		(In millions)	March 31, 2021		March 31, 2020		$ Change
Net cash provided by operating activities		$	54	$	3	$	51
Net cash provided by (used for) operating activities								Net cash provided by (used for) operating activities	$	(59)	$	(76)	$	17
Net cash provided by (used for) investing activities	Net cash provided by (used for) investing activities	71		(45)		116		Net cash provided by (used for) investing activities	(13)		(7)		(6)
Net cash provided by financing activities		162		73		89
Net cash provided by (used for) financing activities								Net cash provided by (used for) financing activities	(3)		159		(162)
Total net cash flows	Total net cash flows	$	287	$	31	$	256	Total net cash flows	$	(75)	$	76	$	(151)

Cash inflows and outflows from changes in operating activities

For the ~~six~~three months ended ~~June 30, 2020,~~March 31, 2021, net cash ~~provided by~~used for operating activities ~~increased~~decreased over the ~~six~~three months ended ~~June 30, 2019,~~March 31, 2020, primarily due to improved ~~inventory management and disciplined expense management.~~

~~Table of Contents~~

profitability.

Cash inflows and outflows from changes in investing activities

For the ~~six~~three months ended ~~June 30, 2020,~~March 31, 2021, net cash ~~provided by~~used for investing activities increased compared to net cash used for investing activities for the ~~six~~three months ended ~~June 30, 2019,~~March 31, 2020, primarily due to ~~$104~~$4 million in ~~net~~ proceeds from the ~~divestiture~~sale of ~~scil.~~property and equipment in the prior year period which reduced the net cash used for investing activities in 2020 with no comparable inflows from property and equipment sales in 2021 and a $2 million increase in purchases of property and equipment in the current period.


Covetrus, Inc. 2021 Q1 Form 10-Q			26

Table of Contents

Cash inflows and outflows from changes in financing activities

For the ~~six~~three months ended ~~June 30, 2020,~~March 31, 2021, net cash used for financing activities increased compared to net cash provided by financing activities ~~increased over~~for the ~~six~~three months ended ~~June 30, 2019,~~March 31, 2020, primarily due to ~~$250~~net inflows in the prior year related to $190 million we borrowed under our Revolving Credit Facility as a precaution in ~~gross proceeds from the issuance of Series A Preferred Stock,~~2020 to increase our cash balance on hand in response to COVID-19 uncertainty, partially offset by $31 million comprised of principal payments for our Term Loan Facility, debt issuance and amendment costs ~~preferred stock issuance costs,~~for our Credit Facilities, and acquisition payments totaling $90 million. During the six months ended June 30, 2019, we had inflows from bank debt of $1.2 billion and our Former Parent of $165 million offset by a dividend payment to Former Parent, principal payments, debt issuance costs, and acquisition of non-controlling interests in subsidiaries totaling $1.3 billion.payments.

Contractual Obligations

We had a material change in our contractual obligations since the end of fiscal year 2020 due to a decrease of $18 million in our purchase obligations. See Note 5 - Commitments and Contingencies.

Off-balance Sheet Arrangements

We did not have any material changes in our ~~contractual obligations~~off-balance sheet arrangements since the end of fiscal year ~~2019~~2020 outside of activities in the ordinary course of business.

~~Off-balance Sheet Arrangements~~

In April 2020, we made a final payment of $9 million for a 2019 acquisition, and as a result, the associated $9 million letter of credit expired, which increases the amount available to be borrowed under our revolving line of credit. As of June 30, 2020, we had $1 million outstanding in standby letters of credit that primarily support our obligations related to our insurance programs and $4 million in surety bonds outstanding in support of various U.S. state registrations for pharmaceutical operations and distributions.

Critical Accounting Estimates

~~Business Acquisitions, Acquired Goodwill, and Intangible Assets~~

Our condensed consolidated financial statements are prepared in accordance with GAAP. The ~~COVID-19 pandemic has brought great uncertainty and volatility to markets across the world, the effects~~preparation of ~~which have forced~~these condensed consolidated financial statements requires us to ~~consider whether the pandemic was a triggering event for goodwill impairment purposes~~make estimates and ~~further, if goodwill was impaired as of March 31, 2020. Testing goodwill for impairment is required at least annually, however, any triggering event occurring between annual tests~~assumptions that ~~would more likely than not reduce the fair value of a reporting unit below its carrying amount requires goodwill to be tested.~~

During the first quarter ended March 31, 2020, we experienced a sustained decline in our share price and a resulting decrease in our market capitalization due to the overall macroeconomic effects of the COVID-19 pandemic. Due to this overall market decline and the uncertainty surrounding COVID-19, we concluded that a triggering event occurred and conducted an interim impairment test of goodwill as of March 31, 2020 by quantitatively compared the fair value of our North America reporting unit (the only reporting unit currently bearing goodwill) to its carrying amount. Using the income-based approach, fair value exceeded the carrying amount as of March 31, 2020.The income-based approach resulted in a fair value that exceeded the carrying amount by $2 million and $156 million at discount rates of 9.0% and 8.5%, respectively.

We did not conduct an impairment test as of June 30, 2020, as no triggering events occurred. We continued to experience strong demand for our prescription management and online pharmacy services during the second quarter 2020, the COVID-19 pandemic has not had a material negative impact on our results of operations or financial condition, and our market capitalization at June 30, 2020 increased 120% over our market capitalization at March 31, 2020. Nevertheless, we consider our North America reporting unit's goodwill to be at risk and changes in our forecast of future operating or financial results, cash flows, share price, market capitalization, or discount rate used when conducting future goodwill impairment tests could affect the ~~estimated fair value of our goodwill-bearing reporting unit and may result~~reported amounts in ~~a goodwill impairment charge in the future.~~

~~Table of Contents~~

~~Income Taxes~~

On March 27, 2020, the CARES Act, a substantial tax-and-spending package, was signed by the President of the United States to provide additional economic stimulus to address the impact of the COVID-19 pandemic. For the six months ended June 30, 2020, there were no material tax impacts to our condensed consolidated financial statements as it relates to the CARES Act. The ultimate impact may differ from this estimate due to changes in interpretations and assumptions, guidance that may be issued, and actions we may take in response to the COVID-19 pandemic and the CARES Act.

~~Other than the items noted above~~, ~~there~~statements. There have been no ~~other~~ material changes in our critical accounting estimates from those disclosed in Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations of our Form 10-K. For a discussion of critical accounting policies and estimates as well as accounting policies adopted, see Note 1 - Business Overview and Significant Accounting Policiesof our Form 10-K.

Recent Accounting Pronouncements

For information on recent accounting pronouncements, see Note 1 - Business Overview and Significant Accounting Policies.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

We ~~have~~continuously evaluate our exposure to ~~market risks related~~foreign currency exchange rate and interest rate risk. There have been no meaningful changes in our exposure to ~~changes~~risk associated with fluctuations in foreign currency exchange rates and interest rates ~~as follows:~~

~~Foreign Currency Risk~~

~~The value of certain foreign currencies as compared~~related to ~~the U.S. dollar and the value of certain of~~ our underlying functional currencies, including our foreign subsidiaries, may affect our financial results. Fluctuations in exchange rates, for which we currently conduct our operations in multiple currencies, may positively or negatively affect revenues, gross margins, and operating expenses, all of which are presented in U.S. dollars. We attempt to offset foreign currency assets and liabilities where and when possible, but have not, as of June 30, 2020, entered into hedging arrangements as the majority of our foreign exchange risk is translation-based, rather than transaction-based. In the future, we may evaluate and decide, to the extent reasonable and practical, to enter into foreign currency forward contracts with financial institutions to manage risk effectively and efficiently. If we were to engage in such hedging transactions, the market risk resulting from foreign currency fluctuations is unlikely to be entirely eliminated. We do not execute derivative financial instruments for trading or speculative purposes.

In addition to the impact that the COVID-19 pandemic is having on global economies, the foreign currency markets, and the ability to potentially execute effective and efficient hedging strategies, we have continuing exposure to Brexit. The primary Brexit risk we face is supply chain-related, specifically for our replenishment of certain inventory stock sourced from U.K. vendors who may manufacture such goods in their subsidiaries outside the U.K. and thus need to import those goods into the U.K. As a result of uncertainty created by Brexit, towards the end of 2020 and after reducing stock levels in response to COVID-19, we plan to rebuild our previously held contingency stock levels by increasing our inventory of such vendor-imported goods by an additional 10% - 20% to satisfy potential customer demand, which action will expose us to incremental foreign exchange risk.

As of June 30, 2020, a hypothetical 5% fluctuation in foreign exchange rates where we conduct our business vis-à-vis the U.S. dollar would have resulted in a change of $2 million in operating income.

~~Interest Rate Risk~~

~~At June 30, 2020, we had~~ variable-rate ~~borrowings of $1.1 billion under the credit facility. We regularly review projected~~ borrowings under the ~~credit facility and the current interest rate environment. Increases~~Credit Facilities from that discussed in the underlying interest rate elections we make with credit facility borrowings will generally negatively affect interest expense, while decreases to the underlying interest rates will generally have a positive influence on our ~~interest expense. COVID-19’s impact on the variable rates to which we are exposed has been a benefit to us so far, however, this could reverse should COVID-19 risks dissipate.~~

~~In 2019, we executed interest rate swap contracts with notional amounts aggregating $500 million that are designated as cash flow hedges. See~~ ~~Note 8 - Derivatives and Financial Instruments. Our earnings are affected by changes in interest rates, however, due to our interest rate swap contracts, the effects are mitigated to an extent.~~Form 10-K.

~~If market interest rates increase 1% over the next 12 months, our net interest expense, after considering the effects of our interest rate swap contracts, would increase by $6 million.~~

~~Table of Contents~~

If market interest rates decrease 1% over the next 12 months (which would result in negative interest rates), the change to our net interest expense, after considering the effects of our interest rate swap contracts, would increase by $3 million.

Our credit facility contains a LIBOR floor of 0.00% while our interest rate swap contracts do not include floors. Our interest expense could, theoretically, increase should LIBOR fall into negative territory. The further LIBOR falls below the fixed rates set within our swap contracts, the more additional interest expense we pay for swap settlements. Conversely, we receive interest for swap settlements when LIBOR is greater than the swaps’ fixed rates. The higher LIBOR rises above the fixed rates, the less interest expense we effectively pay.

Among the many actions taken by the Federal Reserve System to reduce the impact of the COVID-19 pandemic, the decision by its Federal Open Market Committee to lower interest rates has generally benefited us in the form of lower interest expense. This benefit, though, is offset by higher interest rate swap settlement payments by us, the lower interest rates fall. Thus, the market risk resulting from interest rate fluctuations can be mitigated but will not be entirely eliminated through our interest rate swap contracts.


Covetrus, Inc. 2021 Q1 Form 10-Q			27

Table of Contents

Item 4. Controls and Procedures

Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed in reports filed under the Exchange Act, is recorded, processed, summarized, and reported within the specified time periods and accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

Our management, with the participation of our ~~Chief Executive Officer (“CEO”)~~CEO and our ~~Chief Financial Officer (“CFO”),~~CFO, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) promulgated under the Exchange Act) at ~~June 30, 2020.~~March 31, 2021. Based on this evaluation, the CEO and CFO concluded that as of that date, our disclosure controls and procedures required by paragraph (b) of Rules 13a-15 or 15d-15 were not effective, at a reasonable assurance level, because of ~~two~~a material ~~weaknesses~~weakness in internal ~~controls~~control over financial reporting, which we view as an integral part of our disclosure controls and procedures.

Ongoing Remediation of Previously Identified Material Weakness

As previously disclosed in our Form 10-K, ~~and in our Form 10-Q for the quarter ended March 31, 2020,~~ management identified deficiencies in our internal ~~controls~~control over financial reporting which related to ~~(i)~~ the ~~operation of information technology general controls (“ITGCs”) in the areas of logical security and change management in certain financially relevant systems, and (ii)~~ accounting for income taxes and determined that the impact of these deficiencies resulted in a material weakness. This material weakness stemmed from issues associated with the transition to ~~establish~~ expanded in-house tax capabilities and utilization of new tax consultants. ~~A material weakness is~~As a ~~deficiency, or combination~~result of ~~deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company's annual or interim financial statements will~~these issues, our controls to review and analyze our income tax provision and deferred income tax balances were not ~~be prevented or detected on a timely basis.~~effective.

~~Management took the following actions to address the material weakness in ITGCs:~~

•Improved the operation and monitoring of control activities and procedures associated with logical security including user and administrator access to the affected IT systems, including both preventive and detective control activities

•Improved the operation of program change management control activities to track authorizations to changes and emergency change management procedures across the affected IT systems, including both preventive and detective controls activities

•~~Implemented additional training~~We developed remediation plans for ~~resources in the functional areas that support and monitor our IT systems and information generated therefrom~~

~~Management believes that these efforts have effectively addressed the material weakness in ITGCs. However,~~ this material weakness in our internal control over financial reporting will not be considered remediated until (i) the relevant controls are in operation for a sufficient period of time, and (ii) the relevant controls are tested and concluded by management to be designed and operating effectively. The material weakness in ITGCs did not result in any identified misstatements in our financial statements in the current period, and there were no changes in previously released financial results.

~~Management is taking the following actions to address the material weakness in income taxes:~~as follows:

•Increasing oversight by our management in the calculation and reporting of certain tax balances of our global operations

•Enhancing policies, procedures, and controls relating to significant judgments impacting our income tax accounts

•Augmenting our tax accounting resources

•Increasing communication to information providers for tax jurisdiction specific information and

•Strengthening communication and information flows between the tax department and ~~other groups within~~ the ~~organization~~finance group

While Management has made progress to expand our in-house tax resource capabilities and further formalize our internal controls framework, the material weakness in our internal control over financial reporting has not been remediated as of March 31, 2021. It will not be considered remediated until (i) the controls are fully implemented and existing controls are reinforced, (ii) the incremental controls are in operation for a sufficient period of time, and (iii) the controls are tested and concluded by management to be designed and operating effectively. We cannot provide any assurance that these remediation efforts will be successful or that our internal ~~controls~~control over ~~income taxes~~financial reporting will be effective as a result of these ~~remediation~~ efforts. In addition, as we continue to evaluate and work to improve our internal controls over income taxes, management may determine to take additional measures to address control deficiencies or determine to modify the remediation efforts described above.

~~Table of Contents~~

Changes in Internal Control over Financial Reporting

~~Other than as described above, there~~There have been no other changes in our internal control over financial reporting during the most recent quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

See Item 1A. Risk Factors.

Limitations of the Effectiveness of Internal Control

A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the internal control system are met. Because of the inherent limitations of any internal control system, no evaluation of controls can provide absolute assurance that all control issues, if any, within a company have been detected.


Covetrus, Inc. 2021 Q1 Form 10-Q			28

Table of Contents

PART II

Item 1. Legal Proceedings

Refer to Note 105 - Commitments and Contingencies for information relating to legal proceedings.

Item 1A. Risk Factors

In addition to the ~~other~~ information set forth in ~~this Report,~~the Forward-looking Statements in Part I, Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations, you should carefully consider the factors discussed in our Form 10-K. ~~Except as set forth below, there~~There have been no material changes to the risk factors disclosed in ~~the~~our Form 10-K. If any of the events described ~~below or~~ in our Form 10-K actually occur, our business, financial condition, results of operations, and cash flows could be materially and adversely affected, and the trading price of our common stock could decline. Our business could also be affected by additional factors that are not presently known to us or that we currently consider not material. The reader should not consider these factors to be a complete statement of all risks and uncertainties.

We face risks related to health epidemics, including the COVID-19 pandemic, which could have a material adverse effect on our business, results of operations, and could also have an effect on our ability to maintain effective internal controls.

Our business has been and could continue to be adversely affected by a widespread outbreak of contagious disease, including the recent pandemic of respiratory illness caused by a novel coronavirus known as COVID-19. Global health concerns relating to the COVID-19 pandemic have been weighing on the macroeconomic environment, and the pandemic has significantly increased economic volatility and uncertainty.

The pandemic has resulted in government authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. These measures may adversely impact our employees and operations and the operations of our customers, suppliers and business partners, and may negatively impact spending patterns, payment cycles, insurance coverage levels, and demand for our products and services. Such measures may remain in place for a significant period of time and may adversely affect our results of operations. For example, despite an increase in net sales in the first quarter of 2020 relative to the prior year period, net sales weakened from mid-March to late-April and then recovered; however, it is possible that we may experience further declines in the future.

The spread of COVID-19 has caused us to modify our business practices, particularly with respect to our liquidity position and near-term cost structure (including through incremental borrowings on our revolving credit facility to increase cash, which have subsequently been repaid, reduction of non-critical capital expenditures, executive, board, and other senior-level employee compensation reductions that have been reversed subsequent to June 30, 2020, employee furloughs, certain shift eliminations, and a hiring freeze that have been reversed or eased, discretionary spending deferrals, and the deferral of payroll taxes under the CARES Act). We have also decreased our inventory levels to ensure we hold appropriate stock for market conditions, engaged in negotiations to extend payment terms on certain contracts, and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, customers, and business partners. There is no certainty that such actions will be sufficient to mitigate the risks posed by the virus or otherwise be satisfactory to government authorities. If significant portions of our workforce are unable to work effectively, including due to illness, quarantines, social distancing, government actions, or other restrictions in connection with the COVID-19 pandemic, our operations will be impacted, and our stock price could decline.

The extent to which the COVID-19 pandemic impacts our business, results of operations, financial condition, and potentially our control procedures is highly uncertain and cannot be predicted, and will depend on a number of factors including, but not limited to, the duration and spread of the pandemic, its severity, the actions to contain the virus or treat its impact, and how quickly, and to what extent, normal economic and operating activities can resume. For example, in the first quarter of 2020, the COVID-19 pandemic led to increased volatility in our stock price and a sustained decline in our market capitalization which required us to perform an interim impairment review, which could reoccur. In addition, due to current internal policies, many of our employees continue to work remotely, which could have an effect on our internal control over financial reporting. The COVID-19 pandemic could also limit the ability of our customers, suppliers, and business partners to perform, including our customers' ability to make timely payments to us during and following the pandemic. We may also experience a suspension of services from third parties. Even after the COVID-19 pandemic has subsided, we may experience an adverse impact to our business as a result of its global economic impact, including any recession that has occurred or that may occur in the future.

Specifically, difficult macroeconomic conditions, such as decreases in per capita income and level of disposable income, increased and prolonged unemployment, or a decline in consumer confidence as a result of the COVID-19 pandemic could have a

~~Table of Contents~~

material adverse effect on the demand for our products and services. Under difficult economic conditions, consumers may seek to reduce discretionary spending by forgoing our services or choosing not to purchase our products. Decreased demand for our products and services could negatively affect our overall financial performance.

There are no comparable recent events that provide guidance as to the effect of the spread of COVID-19 and, as a result, the ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of COVID-19’s impact on our business, our operations, control procedures, or the global economy as a whole. However, the effects could have a material impact on our results of operations and could cause continued volatility in our stock price, and we will continue to monitor the situation closely.

~~Tax legislation could materially adversely affect our financial results.~~

We are subject to the tax laws and regulations of the United States federal, state, and local governments, as well as foreign jurisdictions. From time to time, various legislative initiatives may be proposed that could materially adversely affect our tax positions. There can be no assurance that our effective tax rate will not be materially adversely affected by legislation resulting from these initiatives.

On December 22, 2017, the U.S. Tax Cuts and Jobs Act of 2017 (the “Tax Act”) was enacted in the United States, which among other things, reduced the corporate tax rate from a top marginal rate of 35% to a flat rate of 21% and limited the ability to deduct net interest expense to 30% of adjusted earnings, in addition to making other significant changes to corporate and international tax provisions. Additionally, on March 27, 2020, the CARES Act, which changes certain aspects of the Tax Act, including provisions relating to the use of net operating losses and the deductibility of business interest expense, was signed into law. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act, as modified by the CARES Act, is uncertain and our business and financial condition could be materially adversely affected. In addition, it is uncertain how various states will respond to the newly enacted federal tax laws.

~~Table of Contents~~

Item 2. Unregistered Sales of Securities and Use of Proceeds

~~Unregistered Sales of Equity Securities and Use of Proceeds~~

On May 19, 2020, we issued 250,000 shares of our 7.5% Series A Preferred Stock, par value of $0.01 per share, for an aggregate purchase price of $250 million (the “Private Placement”). Information with respect to the Private Placement was previously included in Current Reports on Form 8-K filed with the SEC on May 1, 2020 and May 19, 2020.

Purchases of Equity Securities by the Issuer

The following table sets forth information about our purchases of our outstanding common stock during the quarter ended ~~June 30, 2020:~~March 31, 2021:

Period
Total Number of Shares Purchased ⁽¹⁾
Average Price Paid per Share ⁽¹⁾
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate Dollar Value of Shares that May Yet be Purchased Under Plans or Programs
April 2020 40,856 $ 7.66 — $ —
May 2020 32,435 15.39 — —
June 2020 494 15.89 — —
73,785 $ 38.94 — $ —
(1) Shares of common stock we purchased were solely for the cancellation of shares of stock withheld for related tax obligations that occurs upon vesting of restricted shares.


Period	Total Number of Shares Purchased (a)	Average Price Paid Per Share (a)		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet Be Purchased Under Plans or Programs
January 2021	53,696	$	38.54	—	$	—
February 2021	17,170	36.93		—	—
March 2021	22,876	31.84		—	—
	93,742	$	36.61	—	$	—

(a) Shares of common stock we purchased were solely for the cancellation of shares of stock withheld for related tax obligations that occur upon vesting of restricted shares


Covetrus, Inc. 2021 Q1 Form 10-Q			29

Table of Contents

Item 5. Other Information

On May 4, 2021, the Company entered into an amended and restated employment agreement with Michael Ellis. The agreement is attached hereto as Exhibit 10.1.

The Company approved and amended certain performance stock unit agreements which are attached hereto as Exhibits 10.2, 10.3, and 10.4.

Item 6. Exhibits

Exhibit
Number Exhibit Description Form Date No.
3.1
Certificate of Designations Classifying Series A Convertible Preferred Stock
8-K 5/19/2020 3.1
10.1
Investment Agreement, dated as of April 30, 2020, between Covetrus, Inc. and CD&R VFC Holdings, L.P.
8-K 5/1/2020 10.1
10.2
Registration Rights Agreement, dated as of May 19, 2020, by and between Covetrus, Inc. and CD&R VFC Holdings, L.P.
8-K 5/19/2020 10.1
10.3†
Employment Agreement, effective as of June 1, 2020, by and between the Company and Matthew Foulston
8-K/A 6/3/2020 10.1
31.1*
Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).
31.2*
Certification of the Chief Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).
32.1**
Certification of the Chief Executive Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).
32.2**
Certification of the Chief Financial Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).
101.INS* Inline XBRL Instance Document - the instance
document does not appear in the Interactive Data
File because its XBRL tags are embedded within the
Inline XBRL document.
101.SCH* Inline XBRL Taxonomy Extension Schema Document.
101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104* Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

Exhibit
Number

Exhibit Description

Form

Date

No.

10.1†*

Amended and Restated Employment Agreement, effective as of May 4, 2021, by and between the Company and Michael Ellis

10.2†*

Amended Transformation Performance Stock Unit Agreement

10.3†*

2021 Performance Stock Unit Agreement

10.4†*

2021 Performance Stock Unit Agreement for Non-U.S. Participants

31.1*

Certification of the Chief Executive Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).

31.2*

Certification of the Chief Financial Officer, as required by Section 302 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).

32.1**

Certification of the Chief Executive Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).

32.2**

Certification of the Chief Financial Officer, as required by Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350).

101.INS*

Inline XBRL Instance Document - the instance
document does not appear in the Interactive Data
File because its XBRL tags are embedded within the
Inline XBRL document.

101.SCH*

Inline XBRL Taxonomy Extension Schema Document.

101.CAL*

Inline XBRL Taxonomy Extension Calculation Linkbase Document.

101.DEF*

Inline XBRL Taxonomy Extension Definition Linkbase Document.

101.LAB*

Inline XBRL Taxonomy Extension Label Linkbase Document.

101.PRE*

Inline XBRL Taxonomy Extension Presentation Linkbase Document.

104*

Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101).

* Filed herewith

** Furnished herewith

† Indicates management contract or compensatory plan


Covetrus, Inc. 2021 Form 10-Q			30

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

~~Covetrus, Inc.~~COVETRUS, INC.

Date:

~~August 11, 2020~~May 6, 2021

By:

/s/ Benjamin Wolin

Name:

Benjamin Wolin

Title:

President, Chief Executive Officer ~~President~~ and Director
(Principal Executive Officer)

Date:

~~August 11, 2020~~May 6, 2021

By:

/s/ Matthew Foulston

Name:

Matthew Foulston

Title:

Executive Vice President and Chief Financial Officer
(Principal Financial Officer)


Covetrus, Inc. 2021 Form 10-Q			31


	Three Months Ended June 30, 2020
	Common Stock						Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Shareholders' Equity
	Shares		Amount
Balance at March 31, 2020	111,854,439		$	1	$	2,390	$	(1,074)	$	(116)	$	1,201
Net income attributable to Covetrus	—		—		—		54		—		54





Issuance of shares in connection with share-based compensation plans	820,218		—		4		—		—		4
Share-based compensation	—		—		10		—		—		10
Series A preferred stock cash dividend	—		—		—		(2)		—		(2)

Other comprehensive income	—		—		—		—		9		9
Balance at June 30, 2020	112,674,657		$	1	$	2,404	$	(1,022)	$	(107)	$	1,276

	Six Months Ended June 30, 2020
	Common Stock						Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Total Shareholders' Equity
	Shares		Amount
Balance at December 31, 2019	111,620,507		$	1	$	2,381	$	(1,040)	$	(86)	$	1,256
Net income attributable to Covetrus	—		—		—		20		—		20





Issuance of shares in connection with share-based compensation plans	1,054,150		—		4		—		—		4
Share-based compensation	—		—		19		—		—		19
Series A preferred stock cash dividend	—		—		—		(2)		—		(2)

Other comprehensive loss	—		—		—		—		(21)		(21)
Balance at June 30, 2020	112,674,657	��	$	1	$	2,404	$	(1,022)	$	(107)	$	1,276


	Three Months Ended June 30, 2019
	Common Stock					Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Net Former Parent Investment		Total Shareholders' Equity
	Shares	Amount
Balance at March 31, 2019	111,576,343	$	1	$	2,395	$	(21)	$	(81)	$	—	$	2,294
Net (loss) income attributable to Covetrus	—	—		—		(12)		—		2		(10)
Dividend to Former Parent	—	—		(21)		—		—		—		(21)


Shares held in escrow expected to be canceled	—	—		(30)		—		—		—		(30)
Net decrease in Former Parent investment	—	—		—		—		—		(2)		(2)
Issuance of shares in connection with share-based compensation plans	356,148	—		2		—		—		—		2
Share-based compensation	—	—		10		—		—		—		10


Other comprehensive income	—	—		—		—		4		—		4
Balance at June 30, 2019	111,932,491	$	1	$	2,356	$	(33)	$	(77)	$	—	$	2,247

	Six Months Ended June 30, 2019
	Common Stock					Additional Paid-in Capital		Accumulated Deficit		Accumulated Other Comprehensive Loss		Net Former Parent Investment		Total Shareholders' Equity
	Shares	Amount
Balance at December 29, 2018	—	$	—	$	—	$	—	$	(82)	$	1,576	$	1,494
Net (loss) income attributable to Covetrus^(a)	—	—		—		(33)		—		10		(23)
Dividend to Former Parent	—	—		(21)		—		—		(1,153)		(1,174)
Issuance of shares at Separation (including Share Sale investors)	71,693,426	1		608		—		—		(609)		—
Issuance of shares in connection with the Acquisition	39,742,089	—		1,772		—		—		—		1,772
Shares held in escrow expected to be canceled	—	—		(30)		—		—		—		(30)
Net increase in Former Parent investment	—	—		—		—		—		176		176
Issuance of shares in connection with share-based compensation plans	496,976	—		2		—		—		—		2
Share-based compensation	—	—		25		—		—		—		25


Other comprehensive income	—	—		—		—		5		—		5
Balance at June 30, 2019	111,932,491	$	1	$	2,356	$	(33)	$	(77)	$	—	$	2,247


	Three Months Ended June 30, 2020
	Supply Chain Services		Software Solutions		Prescription Management		Eliminations		Total
North America	$	495	$	19	$	110	$	(22)	$	602
Europe	342		2		—		(2)		342
APAC & Emerging Markets	83		2		—		—		85
Eliminations	(3)		—		—		—		(3)
Total Net sales	$	917	$	23	$	110	$	(24)	$	1,026

	Three Months Ended June 30, 2019
	Supply Chain Services		Software Solutions		Prescription Management		Eliminations		Total
North America	$	472	$	20	$	67	$	(7)	$	552
Europe	370		3		—		(3)		370
APAC & Emerging Markets	88		2		—		—		90
Eliminations	(3)		—		—		—		(3)
Total Net sales	$	927	$	25	$	67	$	(10)	$	1,009

	Six Months Ended June 30, 2020
	Supply Chain Services		Software Solutions		Prescription Management		Eliminations		Total
North America	$	956	$	40	$	195	$	(39)	$	1,152
Europe	766		4		—		(6)		764
APAC & Emerging Markets	176		4		—		—		180
Eliminations	(5)		—		—		—		(5)
Total Net sales	$	1,893	$	48	$	195	$	(45)	$	2,091

	Six Months Ended June 30, 2019
	Supply Chain Services		Software Solutions		Prescription Management		Eliminations		Total
North America	$	915	$	42	$	100	$	(8)	$	1,049
Europe	733		5		—		(7)		731
APAC & Emerging Markets	172		4		—		—		176
Eliminations	(6)		—		—		—		(6)
Total Net sales	$	1,814	$	51	$	100	$	(15)	$	1,950


	June 30, 2020		December 31, 2019
Gross definite-lived intangible assets	$	993	$	1,001
Less: Accumulated amortization	(421)		(358)
Other intangibles, net	$	572	$	643


	Commencement Date	Maturity Date	June 30, 2020		December 31, 2019
Revolving line of credit	February 2019	February 2024	$	—	$	—
Term loan payable; quarterly installments of $15 million began March 31, 2020 with balloon payment due at maturity	February 2019	February 2024	1,140		1,200
Loan payable with balloon payment due at maturity	February 2019	March 2023	5		6
Finance lease obligations			1		1
Total debt and other borrowings			1,146		1,207
Less: current maturities			(31)		(62)
Total Long-term debt and other borrowings			1,115		1,145
Less: unamortized debt discount			(20)		(20)
Total Long-term debt and other borrowings, net			$	1,095	$	1,125



Cash Flow Hedging Instruments	Location	Three Months Ended June 30, 2020		Six Months Ended June 30, 2020
Amounts recognized in Other comprehensive income (loss), net of tax	Accumulated other comprehensive loss	$	1	$	(7)


	Six Months Ended June 30, 2020		Year Ended December 31, 2019
Balance at beginning of period	$	10	$	92
Decrease due to redemptions	—		(74)

Net income (loss) attributable to redeemable non-controlling interests	1		(3)

Effect of foreign currency translation (gain) loss attributable to redeemable non-controlling interests	(2)		1
Change to redemption value	—		(6)
Balance at end of period	$	9	$	10


	Derivative Loss		Foreign Currency Translation Loss		Total
Balance at December 29, 2018	$	—	$	(82)	$	(82)
Other comprehensive loss before reclassifications	(1)		(4)		(5)
Reclassified from Accumulated other comprehensive loss to earnings	1		—		1
Balance at December 31, 2019	—		(86)		(86)
Other comprehensive loss before reclassifications	(7)		(16)		(23)
Reclassified from Accumulated other comprehensive loss to earnings	—		2		2
Balance at June 30, 2020	$	(7)	$	(100)	$	(107)


	For the Six Months Ended June 30, 2020
	North America		Europe		APAC & Emerging Markets		Corporate		Eliminations		Total
Net sales	$	1,152	$	764	$	180	$	—	$	(5)	$	2,091
Adjusted EBITDA	$	96	$	34	$	12	$	(31)	$	—	$	111

Reconciliation of net income Attributable to Covetrus to Adjusted EBITDA:
Net income attributable to Covetrus											$	20
Plus: Depreciation and amortization											82
Plus: Interest expense, net											27
Plus: Income tax expense											4
Earnings before interest, taxes, depreciation, and amortization													133
Plus: Share-based compensation													19
Plus: Strategic consulting													9
Plus: Transaction costs^(a)													6
Plus: Separation programs and executive severance													2
Plus: IT infrastructure													2
Plus: Formation of Covetrus^(b)													14
Plus: Capital structure													1
Less: Other income items, net^(c)													(75)


Adjusted EBITDA													$	111

(a) Includes legal, accounting, tax, and other professional fees incurred in connection with acquisitions and divestitures.
(b) Includes professional and consulting fees, duplicative costs associated with transition service agreements, and other costs incurred in connection with the separation from Former Parent and establishing Covetrus as an independent public company.
(c) Includes a $73 million gain on the divestiture of scil and a $1 million gain on the deconsolidation of SAHS. See Note 3 - Divestiture and Equity Method Investment.


	For the Six Months Ended June 30, 2019
	North America		Europe		APAC & Emerging Markets		Corporate		Eliminations		Total
Net sales	$	1,049	$	731	$	176	$	—	$	(6)	$	1,950
Adjusted EBITDA	$	78	$	35	$	8	$	(16)	$	—	$	105

Reconciliation of net loss Attributable to Covetrus to Adjusted EBITDA:
Net loss attributable to Covetrus											$	(23)
Plus: Depreciation and amortization											71
Plus: Interest expense, net											25
Plus: Income tax expense											1
Earnings before interest, taxes, depreciation, and amortization														74
Plus: Share-based compensation											25

Plus: Formation of Covetrus^(a)											14

Plus: Carve-out operating expenses														5
Plus: IT infrastructure													2


Less: Other income items, net														(15)
Adjusted EBITDA											$	105

(a) Includes professional and consulting fees, duplicative costs associated with transition service agreements, and other costs incurred in connection with the separation from Former Parent and establishing Covetrus as an independent public company.


Period	Total Number of Shares Purchased ⁽¹⁾	Average Price Paid per Share ⁽¹⁾		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Approximate Dollar Value of Shares that May Yet be Purchased Under Plans or Programs
April 2020	40,856	$	7.66	—	$	—
May 2020	32,435	15.39		—	—
June 2020	494	15.89		—	—
	73,785	$	38.94	—	$	—

(1) Shares of common stock we purchased were solely for the cancellation of shares of stock withheld for related tax obligations that occurs upon vesting of restricted shares.